International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 75

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 75

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 75

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acalabrutinibum

acalabrutinib	4-{8-amino-3-[(2*S*)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-*a*]pyrazin-1-yl}-*N*-(pyridin-2-yl)benzamide
acalabrutinib	4-{8-amino-3-[(2*S*)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-*a*]pyrazin-1-yl}-*N*-(pyridin-2-yl)benzamide
acalabrutinib	4-{8-amino-3-[(2*S*)-1-(but-2-inoil)pirrolidin-2-il]imidazo[1,5-*a*]pirazin-1-il}-*N*-(piridin-2-il)benzamida

$C_{26}H_{23}N_7O_2$



afasevikumabum #

afasevikumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A) and *Homo sapiens* IL17F (interleukin 17F, IL-17F)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123) -IGHG1*03, G1m3 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (232-232":235-235")-bisdisulfide
afasévikumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A) et *Homo sapiens* IL17F (interleukine 17F, IL-17F)], *Homo sapiens* anticorps monoclonal;

chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123) -IGHG1*03, G1m3 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (232-232'':235-235'')-bisdisulfure

afasevikumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A) y *Homo sapiens* IL17F (interleukina 17F, IL-17F)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123) -IGHG1*03, G1m3 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dímero (232-232'':235-235'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSG  50
INWSSGGIGY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCARDI 100
GGFGEFYWNF GLWGRGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVR SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPATFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                        215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	150-206	267-327	373-431
	22"-96"	150"-206"	267"-327"	373"-431"
Intra-L (C23-C104)	23'-88'	135'-195'		
	23'"-88'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	226-215'	226"-215'"		
Inter-H-H (h 11, h 14)	232-232"	235-235"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilaciónH VH N57: 52, 52" (2% of the glycans)
H CH2 N84.4:
303, 303" (98% of the glycans)
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

aglatimagenum besadenovecum #
aglatimagene besadenovec

adenovirus (serotype 5) non replicant with a deletion in the E1/E2 region containing the herpes virus thymidine kinase gene (*Herpes simplex virus* HSV-tk) under the control of a *Rous sarcoma virus* (RSV) long terminal repeat promoter

aglatimagène bésadénovec

adénovirus (sérotype 5) non répliquant, délété de la région E1/E2, contenant le gène de la thymidine kinase du virus de l'herpès (*virus Herpes simplex* HSV-tk) sous le contrôle de la séquence LTR (terminale longue répétée) du virus du sarcome de Rous (RSV)

aglatimagén besadenovec	adenovirus (serotipo 5), no replicante, con una deleción en la región E1/E2, que contiene el gen de la timidina kinasa del virus del herpes (*Herpes simplex virus* HSV-tk) bajo el control de la secuencia LTR (secuencia larga terminal repetida) del virus del sarcoma de Rous (RSV)

alofanibum

alofanib	3-{[4-methyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoic acid
alofanib	acide 3-{[4-méthyl-2-nitro-5-(pyridin-3-yl)phenyl]sulfamoyl}benzoïque
alofanib	ácido 3-{[4-metil-2-nitro-5-(piridin-3-il)fenil]sulfamoil}benzoico

$C_{19}H_{15}N_3O_6S$



altiratinibum

altiratinib	*N*-{4-[(2-cyclopropanecarboxamidopyridin-4-yl)oxy]-2,5-difluorophenyl}-*N*'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
altiratinib	*N*-{4-[(2-cyclopropanecarboxamidopyridin-4-yl)oxy]-2,5-difluorophényl}-*N*'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
altiratinib	*N*-{4-[(2-ciclopropanocarboxamidopiridin-4-il)oxi]-2,5-difluorofenil}-*N*'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

$C_{26}H_{21}F_3N_4O_4$



amcasertibum

amcasertib	*N*-[2-(diethylamino)ethyl]-2,4-dimethyl-5-{[2-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,2-dihydro-3*H*-indol-3-ylidene]methyl}-1*H*-pyrrole-3-carboxamide
amcasertib	*N*-[2-(diéthylamino)éthyl]-2,4-diméthyl-5-{[2-oxo-5-(2-phényl-1,3-thiazol-4-yl)-1,2-dihydro-3*H*-indol-3-ylidène]méthyl}-1*H*-pyrrole-3-carboxamide

amcasertib

N-[2-(dietilamino)etil]-2,4-dimetil-5-{[5-(2-fenil-1,3-tiazol-4-il)- 2-oxo-1,2-dihidro-3*H*-indol-3-ilideno]metil}-1*H*-pirrol-3-carboxamida

$C_{31}H_{33}N_5O_2S$



apalutamidum

apalutamide

4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-*N*-methylbenzamide

apalutamide

4-{7-[6-cyano-5-(trifluorométhyl)pyridin-3-yl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl}-2-fluoro-*N*-méthylbenzamide

apalutamida

4-{7-[6-ciano-5-(trifluorometil)piridin-3-il]-8-oxo-6-tioxo-5,7-diazaspiro[3.4]octan-5-il}-2-fluoro-*N*-metilbenzamida

$C_{21}H_{15}F_4N_5O_2S$



ascrinvacumabum #

ascrinvacumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* ACVRL1 (activin A receptor type II-like 1, activin receptor-like kinase 1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, transforming growth factor-beta superfamily receptor type I, TGF-B superfamily receptor type I, TSR-I, HHT2, ORW2)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-444) [*Homo sapiens* VH (IGHV4-31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-118) -IGHG2*01, G2m.. (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfide

ascrinvacumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* ACVRL1 (réceptor de type II-like 1 de l'activine A, kinase 1 réceptor-like de l'activine, ALK1, ALK-1, récepteur R3 sérine/thréonine-protéine kinase, SKR3, récepteur de type I de la superfamille du facteur de croissance transformant bêta, récepteur de type I de la superfamille TGF-B, TSR-I, HHT2, ORW2)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-444) [*Homo sapiens* VH (IGHV4-31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-118) -IGHG2*01, G2m.. (CH1 (119-216), charnière (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (220-220'':221-221'':224-224'':227-227'')-tétrakisdisulfure

ascrinvacumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* ACVRL1 (receptor de tipo II-like 1 de la activina A, kinasa 1 receptor-like de la activina, ALK1, ALK-1, receptor R3 serina/treonina-proteína kinasa, SKR3, receptor de tipo I de la superfamilia del factor de crecimiento transformador beta, receptor de type I de la superfamilia TGF-B, TSR-I, HHT2, ORW2)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-444) [*Homo sapiens* VH (IGHV4-31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-118) -IGHG2*01, G2m.. (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimero (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGEYYWNWIR QHPGKGLEWI  50
GYIYYSGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
SVAGFDYWGQ GTLVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSNFGTQTYT 200
CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV 300
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GTSSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPITFG 100
QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                      215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-97 145-201 258-318 364-422
22''-97'' 145''-201'' 258''-318'' 364''-422''
Intra-L (C23-C104) 23'-89' 135'-195'
23'''-89''' 135'''-195'''
Inter-H-L (CH1 10-CL 126) 132-215' 132''-215'''
Inter-H-H (h 4, h 5, h 8, h 11) 220-220'' 221-221'' 224-224'' 227-227''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294''
Fucosylated complex bi-antennary NS0-type glycans / glycanes de type NS0 bi-antennaires complexes fucosylés / glicanos de tipo NS0 biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
C-terminal trimming of the *C*-terminal lysine (K)
H CHS K2:
444, 444''

avacincaptadum pegolum

avacincaptad pegol

5'-*O*-({[6-(1-{(2*RS*)-2,3-bis[ω-methoxypoly(oxyethane-1,2-diyl)]propoxy}formamido)hexyl]oxy}hydroxyphosphoryl)-2'-deoxy-2'-fluoro-cytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-adenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→3')-thymidine

avacincaptad pégol

5'-*O*-({[6-(1-{(2*RS*)-2,3-bis[ω-méthoxypoly(oxyéthane-1,2-diyl)]propoxy}formamido)hexyl]oxy}hydroxyphosphoryl)-2'-déoxy-2'-fluoro-cytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-guanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-adénylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→3')-thymidine

avacincaptad pegol

5'-*O*-({[6-(1-{(2*RS*)-2,3-bis[ω-metoxipoli(oxietano-1,2-diil)]propoxi}formamido)hexil]oxi}hidroxifosforil)-2'-desoxi-2'-fluoro-citidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-guanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-guanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-adenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→3')-timidina

$C_{395}H_{492}F_{21}N_{142}O_{262}P_{39}\ (C_2H_4O)_{2n}$

(3'-5') R-dfIC-mG-dfIC-dfIC-G-dfIC-mG-mG-dfIU-dfIC-dfIU-dfIC-mA-mG-mG-dfIC-G-dfIC-dfIU-mG-mA-mG-dfIU-dfIC-dfIU-mG-mA-mG-dfIU-dfIU-dfIU-A-dfIC-dfIC-dfIU-mG-dfIC-mG3'-3'dT

Legend

dfl = 2'-deoxy-2'-fluoro

m = 2'-*O*-methyl



avelumabum #

avelumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* CD274 (programmed death ligand 1, PDL1, PD-L1, B7 homolog 1, B7H1)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450) (121-450)], (223-215')-disulfide with lambda1 light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (99.00%) -IGLJ1*01) [9.3.10] (1'-110') -IGLC1*02 (111'-216')]; dimer (229-229'':232-232'')-bisdisulfide

avélumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* CD274 (ligand 1 de mort programmée, PDL1, PD-L1, homologue 1 de B7, B7H1)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450) (121-450)], (223-215')-disulfure avec la chaîne légère lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (99.00%) -IGLJ1*01) [9.3.10] (1'-110') -IGLC1*02 (111'-216')]; dimère (229-229'':232-232'')-bisdisulfure

avelumab

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* CD274 (ligando 1 de muerte programada, PDL1, PD-L1, homólogo 1 de B7, B7H1)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450) (121-450)], (223-215')-disulfuro con la cadena ligera lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV2-14*01 (99.00%) -IGLJ1*01) [9.3.10] (1'-110') -IGLC1*02 (111'-216')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYIMMWVRQA PGKGLEWVSS  50
IYPSGGITFY ADTVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARIK 100
LGTVTTVDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPASV SGSPGQSITI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI  50
YDVSNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC SSYTSSSTRV 100
FGTGTKVTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	22'-90'	138'-197'		
	22'"-90'"	138'"-197'"		
Inter-H-L (h 5-CL 126)	223-215'	223"-215'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
450, 450'

belizatinibum

belizatinib

4-fluoro-*N*-(6-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-1-{*cis*-4-[(propan-2-yl)carbamoyl]cyclohexyl}-1*H*-benzimidazol-2-yl)benzamide

bélizatinib

4-fluoro-*N*-(6-{[4-(2-hydroxypropan-2-yl)pipéridin-1-yl]méthyl}-1-{*cis*-4-[(propan-2-yl)carbamoyl]cyclohexyl}-1*H*-benzimidazol-2-yl)benzamide

belizatinib

4-fluoro-*N*-(6-{[4-(2-hidroxipropan-2-il)piperidin-1-il]metil}-1-{*cis*-4-[(propan-2-il)carbamoil]ciclohexil}-1*H*-benzoimidazol-2-il)benzamida

$C_{33}H_{44}FN_5O_3$



bexagliflozinum

bexagliflozin (1*S*)-1,5-anhydro-1-*C*-[4-chloro-3-({4-[2-(cyclopropyloxy)ethoxy]phenyl}methyl)phenyl]-D-glucitol

bexagliflozine (1*S*)-1,5-anhydro-1-*C*-[4-chloro-3-({4-[2-(cyclopropyloxy)éthoxy]phényl}méthyl)phényl]-D-glucitol

bexagliflozina (1*S*)-1,5-anhidro-1-*C*-[3-({4-[2-(ciclopropiloxi)etoxi]fenil}metil)-4-clorofenil]-D-glucitol

$C_{24}H_{29}ClO_7$



bictegravirum

bictegravir (2*R*,5*S*,13a*R*)-8-hydroxy-7,9-dioxo-*N*-[(2,4,6-trifluorophenyl)methyl]-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazepine-10-carboxamide

bictégravir (2*R*,5*S*,13a*R*)-8-hydroxy-7,9-dioxo-*N*-[(2,4,6-trifluorophényl)méthyl]-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanopyrido[1',2':4,5]pyrazino[2,1-*b*][1,3]oxazépine-10-carboxamide

bictegravir	(2*R*,5*S*,13a*R*)-8-hidroxi-7,9-dioxo-*N*-[(2,4,6-trifluorofenil)metil]-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-*b*][1,3]oxazepina-10-carboxamida $C_{21}H_{18}F_3N_3O_5$ 

bleselumabum #

bleselumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* CD40 (tumor necrosis factor receptor superfamily member 5, TNFRSF5)], human monoclonal antibody; gamma4 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-121) -IGHG4*01 (CH1 (122-219), hinge S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (98.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (227-227":230-230")-bisdisulfide
blésélumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* CD40 (membre 5 de la superfamille des récepteurs du TNF, TNFRSF5)], anticorps monoclonal humain; chaîne lourde gamma4 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-121) -IGHG4*01 (CH1 (122-219), charnière S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (98.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimère (227-227":230-230")-bisdisulfure
bleselumab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD40 (miembro 5 de la superfamilia de receptores del TNF, TNFRSF5)], anticuerpo monoclonal humano; cadena pesada gamma4 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.13] (1-121) -IGHG4*01 (CH1 (122-219), bisagra S10>P (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (98.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QLQLQESGPG LLKPSETLSL TCTVSGGSIS SPGYYGGWIR QPPGKGLEWI  50
GSIYKSGSTY HNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCTRP 100
VVRYFGWFDP WGQGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFEGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD  50
ASNLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-97 148-204 262-322 368-426
22"-97" 148"-204" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 133'-193'
23'"-88'" 133'"-193'"
Inter-H-L (CH1 10-CL 126) 135-213' 135"-213'"
Inter-H-H (h 8, h 11) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

brigatinibum

brigatinib — 2-[(5-chloro-2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}pyrimidin-4-yl)amino]phenyl}dimethyl-λ^5-phosphanone

brigatinib — 2-[(5-chloro-2-{2-méthoxy-4-[4-(4-méthylpipérazin-1-yl)pipéridin-1-yl]anilino}pyrimidin-4-yl)amino]phényl}diméthyl-λ^5-phosphanone

brigatinib — 2-[(5-cloro-2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]anilino}pirimidin-4-il)amino]fenil}dimetil-λ^5-fosfanona

$C_{29}H_{39}ClN_7O_2P$



capsaicinum

capsaicin — (6*E*)-*N*-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide

capsaïcine — (6*E*)-*N*-[(4-hydroxy-3-méthoxyphényl)méthyl]-8-méthylnon-6-énamide

capsaicina — (6*E*)-*N*-[(4-hidroxi-3-metoxifenil)metil]-8-metilnon-6-enamida

$C_{18}H_{27}NO_3$



cenerimodum

cenerimod	(2*S*)-3-{4-[5-(2-cyclopentyl-6-methoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy}propane-1,2-diol
cénérimod	(2*S*)-3-{4-[5-(2-cyclopentyl-6-méthoxypyridin-4-yl)-1,2,4-oxadiazol-3-yl]-2-éthyl-6-méthylphénoxy}propane-1,2-diol
cenerimod	(2*S*)-3-{4-[5-(2-ciclopentil-6-metoxipiridin-4-il)-1,2,4-oxadiazol-3-il]-2-etil-6-metilfenoxi}propano-1,2-diol

$C_{25}H_{31}N_3O_5$



cenobamatum

cenobamate	(1*R*)-1-(2-chlorophenyl)-2-(2*H*-tetrazol-2-yl)ethyl carbamate
cénobamate	carbamate de (1*R*)-1-(2-chlorophényl)-2-(2*H*-tétrazol-2-yl)éthyle
cenobamato	carbamato de (1*R*)-1-(2-clorofenil)-2-(2*H*-tetrazol-2-il)etilo

$C_{10}H_{10}ClN_5O_2$



cergutuzumabum amunaleukinum #

cergutuzumab amunaleukin	immunoglobulin G1-kappa fused to IL2 (interleukin 2), anti-[*Homo sapiens* CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e)], humanized monoclonal antibody fused to IL2; gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), hinge (220-234), CH2 L1.3>A (238), L1.2>A (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S (370), L24>A (372), Y86>V (411) (345-449), CHS (450-451)) (122-451)], (224-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; gamma1 heavy chain fused to IL2 (1''-598'') [humanized VH (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1''-121'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122''-219''), hinge (220''-234''), CH2 L1.3>A (238''), L1.2>A (239''), P114>G (333'') (235''-344''), CH3 S10>C (358''), T22>W (370''), (345''-449''), CHS K2>del (450'')) (122''-450'') -15-mer (tris(tetraglycyl-seryl)) linker (451''-465'') -*Homo sapiens* IL2 (Pr21-153) T23>A (468''), F62>A (507''), Y65>A (510''), L92>G (547''), C145>A (590'') (466''-598'')], (224''-215''')-disulfide with kappa light chain (1'''-215''') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'''-108''') -*Homo sapiens* IGKC*01, Km3 (109'''-215''')]; dimer (230-230'':233-233'')-bisdisulfide
cergutuzumab amunaleukine	immunoglobuline G1-kappa fusionnée à l'IL2 (interleukine 2), anti-[*Homo sapiens* CEACAM5 (molécule d'adhésion cellulaire 5 apparentée à l'antigène carcinoembryonaire, CEA, CD66e)], anticorps monoclonal humanisé fusionné à l'IL2; chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), charnière (220-234), CH2 L1.3>A (238), L1.2>A (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S (370), L24>A (372), Y86>V (411) (345-449), CHS (450-451)) (122-451)], (224-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; chaîne lourde gamma1 fusionnée à l'IL2 (1''-598'') [VH humanisé (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1''-121'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122''-219''), charnière (220''-234''), CH2 L1.3>A (238''), L1.2>A (239''), P114>G (333'') (235''-344''), CH3 S10>C (358''), T22>W (370''), (345''-449''), CHS K2>del (450'')) (122''-450'') -15-mer (tris(tétraglycyl-séryl)) linker (451''-465'') -*Homo sapiens* IL2 (Pr21-153) T23>A (468''), F62>A (507''), Y65>A (510''), L92>G (547''), C145>A (590'') (466''-598'')], (224''-215''')- disulfure avec la chaîne légère kappa (1'''-215''') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'''-108''') -*Homo sapiens* IGKC*01, Km3 (109'''-215''')]; dimère (230-230'':233-233'')-bisdisulfure

cergutuzumab amunaleukina

inmunoglobulina G1-kappa fusionada con IL2 (interleukina 2), anti-[*Homo sapiens* CEACAM5 (molécula de adhesión celular 5 relacionada con el antígeno carcinoembrionario, CEA, CD66e)], anticuerpo monoclonal humanizado fusionado IL2;
cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), bisagra (220-234), CH2 L1.3>A (238), L1.2>A (239), P114>G (333) (235-344), CH3 Y5>C (353), T22>S (370), L24>A (372), Y86>V (411) (345-449), CHS (450-451)) (122-451)], (224-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; cadena pesada fusionada con 'IL2 (1''-598'') [VH humanizado (*Homo sapiens* IGHV1-18*01 (82.70%) -(IGHD)-IGHJ6*01) [8.8.14] (1''-121'') -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122''-219''), bisagra (220''-234''), CH2 L1.3>A (238''), L1.2>A (239''), P114>G (333'') (235''-344''), CH3 S10>C (358''), T22>W (370''), (345''-449''), CHS K2>del (450'')) (122''-450'') -15-mer (tris(tetraglicil-seril)) espaciador (451''-465'') -*Homo sapiens* IL2 (Pr21-153) T23>A (468''), F62>A (507''), Y65>A (510''), L92>G (547''), C145>A (590'') (466''-598'')], (224''-215''')- disulfuro con la cadena ligera kappa (1'''-215''') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'''-108''') -*Homo sapiens* IGKC*01, Km3 (109'''-215''')]; dímero (230-230'':233-233'')-bisdisulfuro

Heavy chain H/ Chaîne lourde H/ Cadena pesada H
```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT EFGMNWVRQA PGQGLEWMGW  50
INTKTGEATY VEEFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARWD 100
FAYYVEAMDY WGQGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPEAAG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALGAPIEKTI SKAKGQPREP 350
QVCTLPPSRD ELTKNQVSLS CAVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL VSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Heavy chain H'' (fused to IL2) / Chaîne lourde H'' (fusionnée to IL2) / Cadena pesada H'' (fusionada con IL2)
```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT EFGMNWVRQA PGQGLEWMGW  50
INTKTGEATY VEEFKGRVTF TTDTSTSTAY MELRSLRSDD TAVYYCARWD 100
FAYYVEAMDY WGQGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPEAAG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALGAPIEKTI SKAKGQPREP 350
QVYTLPPCRD ELTKNQVSLW CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
GGGGSGGGGS GGGGSAPASS STKKTQLQLE HLLLDLQMIL NGINNYKNPK 500
LTRMLTAKFA MPKKATELKH LQCLEEELKP LEEVLNGAQS KNFHLRPRDL 550
ISNINVIVLE LKGSETTFMC EYADETATIV EFLNRWITFA QSIISTLT   598
```

Light chain / Chaîne légère / Cadena ligera
```
DIQMTQSPSS LSASVGDRVT ITCKASAAVG TYVAWYQQKP GKAPKLLIYS  50
ASYRKRGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCHQ YYTYPLFTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
Intra-H (C23-C104) 22''-96'' 148''-204'' 265''-325'' 371''-429''
-IL2 (Pr C78-C125) 523''-570''
Intra-L (C23-C104) 23'-88' 135'-195'
23'''-88''' 135'''-195'''
Inter-H-L (h 5-CL 126) 224-215' 224''-215'''
Inter-H-H (h 11, h 14) 230-230'' 233-233''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
451

ciraparantagum

ciraparantag — $N^1,N^{1'}$-[piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide

ciraparantag — $N^1,N^{1'}$-[pipérazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide

ciraparantag — $N^1,N^{1'}$-[piperazina-1,4-diilbis(propano-1,3-diil)]bis-L-argininamida

$C_{22}H_{48}N_{12}O_2$



cobitolimodum

cobitolimod — *all-P-ambo*-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxycytidine

cobitolimod — *tout-P-ambo*-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxycytidine

cobitolimod — *todo-P-ambo*-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxicitidina

$C_{185}H_{233}N_{73}O_{106}P_{18}S_6$

(3'-5')-d-(G-G-A-A-C-A-G-T-T-C-G-T-C-C-A-T-G-G-C)

Modified residues / Nucléotides modifiés / Nucleótidos modificados

B = A , G , T

(*P-RS*)-2'-deoxy-*P*-thionucleyl

(*P-RS*)-2'-désoxy-*P*-thionucléyle

(*P-RS*)-2'-deoxi-*P*-thionucleil



and epimer at P
et l'épimère en P
y el epímero al P

daprodustatum

daprodustat — *N*-[(1,3-dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl]glycine

daprodustat — *N*-[(1,3-dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl)carbonyl]glycine

daprodustat — *N*-[(1,3-diciclohexilhexahidro-2,4,6-trioxopirimidin-5-il)carbonil]glicina

$C_{19}H_{27}N_3O_6$



difelikefalinum

difelikefalin — 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid

difélikéfaline — acide 4-amino-1-(D-phénylalanyl-D-phénylalanyl-D-leucyl-D-lysyl)pipéridine-4-carboxylique

difelicefalina — ácido 4-amino-1-(D-fenilalanil-D-fenilalanil-D-leucil-D-lisil)piperidina-4-carboxílico

$C_{36}H_{53}N_7O_6$



dusquetidum

dusquetide — L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alaninamide

dusquétide — L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alaninamide

dusquetida — L-arginil-L-isoleucil-L-valil-L-prolil-L-alaninamida

$C_{25}H_{47}N_9O_5$



efpegsomatropinum #

efpegsomatropin — recombinant human growth hormone (somatropin) and human immunoglobulin G4 Fc fragment dimer, produced in *Escherichia coli* (nonglycosylated), linked together with polyethylene glycol derivative linker: $N^{\alpha.1}$,$N^{1.9'}$-[ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyethylene)] human growth hormone, human immunoglobulin G4 Fc fragment (IGHG4*01 H-CH2-CH3)-(9'-229')-peptide dimer (11'-11'')-disulfide

efpègsomatropine — hormone de croissance humaine (somatropine) et dimère du fragment Fc de l'IgG4 humain, recombinants produits par *Escherichia coli* (non glycosylés), liés par un pont dérivé du polyéthylèneglycol : $N^{\alpha.1}$,$N^{1.9'}$- [ω-(oxypropane-1,3-diyl)-α-(propane-1,3-diyl)poly(oxyéthylène)] hormone de croissance humaine, (11'-11'')-disulfure du dimère du fragment Fc de l'immunoglobuline G4 humaine (IGHG4*01 H-CH2-CH3)-(9'-229')-peptide

efpegsomatropina — hormona humana de crecimiento (somatropina) y dímero del fragmento Fc de la IgG4 humana, recombinantes, producidos por *Escherichia coli* (no glicosilados), unidos por un puente derivado del polietilenglicol : $N^{\alpha.1}$,$N^{1.9'}$- [ω-(oxipropano-1,3-diil)-α-(propano-1,3-diil)poli(oxietileno)] hormona humana de crecimiento, (11'-11'')-disulfuro del dímero del fragmento Fc de la inmunoglobulina G4 humana (IGHG4*01 H-CH2-CH3)-(9'-229')-péptido

Growth Hormone / Hormone de croissance humaine / Hormona humana de crecimiento

```
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT 50
SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS 150
HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F          191
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4

```
         PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50'
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100'
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150'
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200'
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                        229'
```

hIGHG4 Fc monomer / Monomère du Fc de hIGHG4 / Monómero de Fc de hIGHG4

```
        PS CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50''
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100''
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150''
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200''
EGNVFSCSVM HEALHNHYTQ KSLSLSLGK                        229''
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

11'-11'' 43'-103' 43''-103'' 53-165 149'-207' 149''-207'' 182-189

Modified residues / Résidus modifiés / Restos modificados



elamipretidum

elamipretide — D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide

élamiprétide — D-arginyl-2,6-diméthyl-L-tyrosyl-L-lysyl-L-phénylalaninamide

elamipretida — D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida

$C_{32}H_{49}N_9O_5$



emicizumabum #

emicizumab — immunoglobulin G4-kappa, bispecific, anti-[*Homo sapiens* F9a (activated coagulation factor F9, activated coagulation factor IX) and anti-[*Homo sapiens* F10 (coagulation factor 10, coagulation factor X)], humanized monoclonal antibody;
gamma4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-123)), IGHG4*01 (CH1 K100>Q (202) (124-221), hinge S10>P (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3 E12>K (359), R88>K (412), H115>R (438), L125>P (448) (344-448), CHS>del) (124-448)], (137-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')];
gamma4 heavy chain (1-444) [VH (*Homo sapiens* IGHV1-2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E (111''), T123>L (114'') (1''-119'')), IGHG4*01 (CH1 A100>Q (198'') (120''-217''), hinge S10>P (227'') (218''-229''), CH2 F84.3>Y (295''), (230''-339''), CH3 R88>K (408), K119>E (438), L125>P (444) (340''-444''), CHS>del) (120''-444'')], (133''-214''')-disulfide with kappa light chain (1'''-214''') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'''-107''') -*Homo sapiens* IGKC*01, Km3 (108'''-214''')]; dimer (229-225":232-228")-bisdisulfide

émicizumab	immunoglobuline G4-kappa, bispécifique, anti-[*Homo sapiens* F9a (facteur de coagulation F9 activé, facteur de coagulation IX activé) et anti-[*Homo sapiens* F10 (facteur de coagulation 10, facteur de coagulation X)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-448) [VH humanisé (*Homo sapiens* IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-123)), IGHG4*01 (CH1 K100>Q (202) (124-221), S10>P (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3 E12>K (359), R88>K (412), H115>R (438), L125>P (448) (344-448), CHS>del) (124-448)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; chaîne lourde gamma4 (1-444) [VH humanisé (*Homo sapiens* IGHV1-2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E (111"), T123>L (114") (1"-119")), IGHG4*01 (CH1 A100>Q (198") (120"-217"), charnière S10>P (227") (218"-229"), CH2 F84.3>Y (295"), (230"-339"), CH3 R88>K (408), K119>E (438), L125>P (444) (340"-444"), CHS>del) (120"-444")], (133"-214"')-disulfure avec la chaîne légère kappa (1"'-214"') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1"'-107"') -*Homo sapiens* IGKC*01, Km3 (108"'-214"')]; dimère (229-225":232-228")-bisdisulfure
emicizumab	inmunoglobulina G4-kappa, biespecífica, anti-[*Homo sapiens* F9a (factor de coagulación F9 activado, factor de coagulación IX activado) y anti-[*Homo sapiens* F10 (factor de coagulación 10, factor de coagulación X)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-448) [VH humanizado (*Homo sapiens* IGHV3-23*04 (87.80%) -(IGHD)-IGHJ4*01 (1-123)), IGHG4*01 (CH1 K100>Q (202) (124-221), S10>P (231) (222-233), CH2 F84.3>Y (299) (234-343), CH3 E12>K (359), R88>K (412), H115>R (438), L125>P (448) (344-448), CHS>del) (124-448)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; cadena pesada gamma4 (1-444) [VH humanizado (*Homo sapiens* IGHV1-2*02 (75.50%) -(IGHD)-IGHJ6*03 Q120>E (111"), T123>L (114") (1"-119")), IGHG4*01 (CH1 A100>Q (198") (120"-217"),bisagra S10>P (227") (218"-229"), CH2 F84.3>Y (295"), (230"-339"), CH3 R88>K (408), K119>E (438), L125>P (444) (340"-444"), CHS>del) (120"-444")], (133"-214"')-disulfuro con la cadena ligera kappa (1"'-214"') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ4*01) [6.3.9] (1"'-107"') -*Homo sapiens* IGKC*01, Km3 (108"'-214"')]; dímero (229-225":232-228")-bisdisulfuro

Heavy chain anti-F9a/ Chaîne lourde anti-F9a/ Cadena pesada anti-F9a

```
QVQLVESGGG LVQPGGSLRL SCAASGFTFS YYDIQWVRQA PGKGLEWVSS  50
ISPSGQSTYY RREVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRT 100
GREYGGGWYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350
VYTLPPSQKE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QEGNVFSCSV MHEALHNRYT QKSLSLSP   448
```

Heavy chain anti-F10/ Chaîne lourde anti-F10/ Cadena pesada anti-F10

```
QVQLVQSGSE LKKPGASVKV SCKASGYTFT DNNMDWVRQA PGQGLEWMGD  50
INTRSGGSIY NEEFQDRVIM TVDKSTDTAY MELSSLRSED TATYHCARRK 100
SYGYYLDEWG EGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQEGN VFSCSVMHEA LHNHYTQESL SLSP        444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASRNIE RQLAWYQQKP GQAPELLIYQ  50
ASRKESGVPD RFSGSRYGTD FTLTISSLQP EDIATYYCQQ YSDPPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 150-206 264-324 370-428
22"-96" 146"-202" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 137-214' 133"-214'"
Inter-H-H (h 8, h 11) 229-225" 232-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenario complejos fucosilados

enasidenibum

enasidenib — 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol

énasidénib — 2-méthyl-1-[(4-[6-(trifluorométhyl)pyridin-2-yl]-6-{[2-(trifluorométhyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol

enasidenib — 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2-(trifluorometil)piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan-2-ol

$C_{19}H_{17}F_6N_7O$



enerisantum

enerisant — [1-(4-{3-[(2*R*)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1*H*-pyrazol-4-yl](morpholin-4-yl)methanone

énérisant [1-(4-{3-[(2*R*)-2-méthylpyrrolidin-1-yl]propoxy}phényl)-1*H*-pyrazol-4-yl](morpholin-4-yl)méthanone

enerisant 1-(4-{3-[(2*R*)-2-metilpirrolidin-1-il]propoxi}fenil)-1*H*-pirazol-4-il](morfolin-4-il)metanona

$C_{22}H_{30}N_4O_3$



entrectinibum

entrectinib *N*-{5-[(3,5-difluorophenyl)methyl]-1*H*-indazol-3-yl}-4-(4-methylpiperazin-1-yl)-2-[(oxan-4-yl)amino]benzamide

entrectinib *N*-{5-[(3,5-difluorophényl)méthyl]-1*H*-indazol-3-yl}-4-(4-méthylpipérazin-1-yl)-2-[(oxan-4-yl)amino]benzamide

entrectinib *N*-{5-[(3,5-difluorofenil)metil]-1*H*-indazol-3-il}-4-(4-metilpiperazin-1-il)-2-[(oxan-4-il)amino]benzamida

$C_{31}H_{34}F_2N_6O_2$ 1108743-60-7



erdafitinibum

erdafitinib N^1-(3,5-dimethoxyphenyl)-N^1-[3-(1-methyl-1*H*-pyrazol-4-yl)quinoxalin-6-yl]-N^2-(propan-2-yl)ethane-1,2-diamine

erdafitinib N^1-(3,5-diméthoxyphényl)-N^1-[3-(1-méthyl-1*H*-pyrazol-4-yl)quinoxalin-6-yl]-N^2-(propan-2-yl)éthane-1,2-diamine

erdafitinib N^1-(3,5-dimetoxifenil)-N^1-[3-(1-metil-1*H*-pirazol-4-il)quinoxalin-6-il]-N^2-(propan-2-il)etano-1,2-diamina

$C_{25}H_{30}N_6O_2$



etripamilum

etripamil	methyl 3-(2-{[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl](methyl)amino}ethyl)benzoate
étripamil	3-(2-{[(4S)-4-cyano-4-(3,4-diméthoxyphényl)-5-méthylhexyl](méthyl)amino}éthyl)benzoate de méthyle
etripamilo	3-(2-{[(4S)-4-ciano-4-(3,4-dimetoxifenil)-5-metilhexil](metil)amino}etil)benzoato de metilo

$C_{27}H_{36}N_2O_4$



evenamidum

evenamide	2-{[2-(3-butoxyphenyl)ethyl]amino}-*N*,*N*-dimethylacetamide
événamide	2-{[2-(3-butoxyphényl)éthyl]amino}-*N*,*N*-diméthylacétamide
evenamida	2-{[2-(3-butoxifenil)etil]amino}-*N*,*N*-dimetilacetamida

$C_{16}H_{26}N_2O_2$



evocalcetum

evocalcet	{4-[(3*S*)-3-{[(1*R*)-1-(naphthalen-1-yl)ethyl]amino}pyrrolidin-1-yl]phenyl}acetic acid
évocalcet	acide {4-[(3*S*)-3-{[(1*R*)-1-(naphtalén-1-yl)éthyl]amino}pyrrolidin-1-yl]phényl}acétique

evocalcet

ácido {4-[(3*S*)-3-{[(1*R*)-1-(naftalen-1-il)etil]amino}pirrolidin-1-il]fenil}acético

$C_{24}H_{26}N_2O_2$



ezutromidum

ezutromid

5-(ethanesulfonyl)-2-(naphthalen-2-yl)-1,3-benzoxazole

ézutromid

5-(éthanesulfonyl)-2-(naphtalén-2-yl)-1,3-benzoxazole

ezutromid

5-(etanosulfonil)-2-(naftalen-2-il)-1,3-benzoxazol

$C_{19}H_{15}NO_3S$



fitusiranum

fitusiran

small interfering RNA (siRNA) inhibiting antithrombin liver production:
duplex of [(2*S*,4*R*)-1-{30-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecyl]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen (*P*-*RS*)-2'-deoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-(*P*-*RS*)-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylate and

	and (*P*-*RS*)-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-(*P*-*RS*)-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-(*P*-*RS*)-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-(*P*-*RS*)-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methylguanosine
fitusiran	petit ARN interférant inhibant la production hépatique d'antithrombine: duplex de l'hydrogéno-(*P*-*RS*)-2'-deoxy-2'-fluoro-*P*-thioguanylyl-(3'→5')-(*P*-*RS*)-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluoroadénylate de [(2*S*,4*R*)-1-{30-(2-acétamido-2-désoxy-β-D-galactopyranosyl)-14,14-bis[16-(2-acétamido-2-désoxy-β-D-galactopyranosyl)-5,11-dioxo-2,16-dioxa-6,10-diazahexadécyl]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoyl}-4-hydroxypyrrolidin-2-yl]méthyle et du(*P*-*RS*)-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')(*P*-*RS*)-2'-désoxy-2'-fluoro-*P*-thiouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-(*P*-*RS*)-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-(*P*-*RS*)-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthylguanosine

fitusirán

ARN pequeño de interferencia que inhibe la producción hepática de antitrombina:
dúplex de hidrógeno-(*P*-*RS*)-2'-desoxi-2'-fluoro-*P*-tioguanilil-(3'→5')-(*P*-*RS*)-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxi-2'-fluorouridill-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroadenilato de [(2*S*,4*R*)-1-{30-(2-acetamido-2-desoxi-β-D-galactopiranosil)-14,14-bis[16-(2-acetamido-2-desoxi-β-D-galactopiranosil)-5,11-dioxo-2,16-dioxa-6,10-diazahexadecil]-12,19,25-trioxo-16,30-dioxa-13,20,24-triazatriacontanoil}-4-hidroxipirrolidin-2-il]metil y de (*P*-*RS*)-2'-*O*-metil-*P*-tiouridilil-(3'→5') (*P*-*RS*)-2'-desoxi-2'-fluoro-*P*-tiouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroadenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-(*P*-*RS*)-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-(*P*-*RS*)-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metilguanosina

$C_{520}H_{679}F_{21}N_{175}O_{309}P_{43}S_6$



fosnetupitantum

fosnetupitant

{4-[5-{2-[3,5-bis(trifluoromethyl)phenyl]-*N*,2-dimethylpropanamido}-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl}methyl hydrogen phosphate

fosnétupitant

hydrogénophosphate de {4-[5-{2-[3,5-bis(trifluorométhyl)phényl]-*N*,2-diméthylpropanamido}-4-(2-méthylphényl)pyridin-2-yl]-1-méthylpipérazin-1-ium-1-yl}méthyle

fosnetupitant

hidrógenofosfato de {4-[5-{2-[3,5-bis(trifluorometil)fenil]-*N*,2-dimetilpropanamido}-4-(2-metilfenil)piridin-2-il]-1-metilpiperazin-1-io-1-il}metilo

$C_{31}H_{35}F_6N_4O_5P$



glembatumumabum vedotinum #

glembatumumab vedotin

immunoglobulin G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotein (transmembrane) nmb, glycoprotein transmembrane NMB, glycoprotein nonmetastatic melanoma protein B, CG56972, osteoactivin, hematopoietic growth factor inducible neurokinin-1 type, HGFIN) extracellular domain], *Homo sapiens* monoclonal antibody conjugated to auristatin E;
gamma2 heavy chain (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01, G2m.. (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide; conjugated, on an average of 5 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

glembatumumab védotine

immunoglobuline G2-kappa, anti-[*Homo sapiens* GPNMB (glycoprotéine (transmembranaire) nmb, glycoprotéine transmembranaire NMB, protéine B glycoprotéine de mélanome non métastatique, CG56972, ostéoactivine, facteur de croissance hématopoïétique inductible type neurokinine-1, HGFIN) domaine extracellulaire], *Homo sapiens* anticorps monoclonal conjugué à l'auristatine E;
chaîne lourde gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01, G2m.. (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (221-221'':222-222'':225-225'':228-228'')-tétrakisdisulfure; conjugué, sur 5 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

glembatumumab vedotina

inmunoglobulina G2-kappa, anti-[*Homo sapiens* GPNMB (glicoproteína (transmembrana) nmb, glicoproteina transmembrana NMB, proteína B glicoproteína de melanoma no metastásico, CG56972, osteoactivina, factor de crecimiento hematopoyético inducible tipo neurokinina-1, HGFIN) dominio extracelular], *Homo sapiens* anticuerpo monoclonal conjugado con auristatina E;
cadena pesada gamma2 (1-445) [*Homo sapiens* VH (IGHV4-31*02 (94.90%) -(IGHD)-IGHJ4*01) [10.7.11] (1-119) -IGHG2*01, G2m.. (CH1 (120-217), bisagra (218-229), CH2 (230-338), CH3 (339-443), CHS (444-445)) (120-445)], (133-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (96.80%) -IGKJ1*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dímero (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfuro; conjugado, en una media de 5 restos cisteinil, con monometilauristatina E (MMAE), mediante un espaciadorescindible de tipo maleimidocaproil-valil-citrulinil-*p*-aminobenciloxicarbonil (mc-val-cit-PABC)
La fracción *vedotina*, la pueden encontrar en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SFNYYWSWIR HHPGKGLEWI  50
GYIYYSGSTY SNPSLKSRVT ISVDTSKNQF SLTLSSVTAA DTAVYYCARG 100
YNWNYFDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSNFGTQTY 200
TCNVDHKPSN TKVDKTVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVD NNLVWYQQKP GQAPRLLIYG  50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPPWTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 146-202 259-319 365-423
22"-97" 146"-202" 259"-319" 365"-423"
Intra-L (C23-C104) 23'-88' 135'-195'
23'"-88'" 135'"-195'"
Inter-H-L (CH1 10-CL 126) 133-215' 133"-215'"
Inter-H-H (h 4, h 5, h 8, h 11) 221-221" 222-222" 225-225" 228-228"
*Two or three of the inter-chain disulfide bridges are not present, an average of 5 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 5 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 5 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

graunimotidum
graunimotide

L-lysyl-L-arginyl-L-tyrosyl-L-phenylalanyl-L-lysyl-L-leucyl-L-seryl-L-histidyl-L-leucyl-L-glutaminyl-L-methionyl-L-histidyl-L-seryl-L-arginyl-L-lysyl-L-histidine;
human Wilms tumor protein (WT33) (332-347)-peptide

graunimotide

L-lysyl-L-arginyl-L-tyrosyl-L-phénylalanyl-L-lysyl-L-leucyl-L-séryl-L-histidyl-L-leucyl-L-glutaminyl-L-méthionyl-L-histidyl-L-séryl-L-arginyl-L-lysyl-L-histidine;
protéine tumorale Wilms humaine (WT33) (332-347)-peptide

graunimotida

L-lisil-L-arginil-L-tiyrosil-L-fenilalanil-L-lisil-L-leucil-L-seril-L-histidil-L-leucil-L-glutaminil-L-metionyl-L-histidil-L-seril-L-arginil-L-lisil-L-histidina;
proteína de tumor de Wilms humano (WT33) (332-347)-péptido

$C_{94}H_{150}N_{32}O_{21}S$

H–Lys–Arg–Tyr–Phe–Lys–Leu–Ser–His–Leu–
Gln–Met–His–Ser–Arg–Lys–His–OH
10 16

guadecitabinum

guadecitabine

2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine

guadécitabine

2'-déoxy-5-azacytidylyl-(3'→5')-2'-déoxyguanosine

guadecitabina

2'-desoxi-5-azacitidilil-(3'→5')-2'-desoxiguanosina

$C_{18}H_{24}N_9O_{10}P$



inebilizumabum

inebilizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], humanized monoclonal antibody;
gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (230-230":233-233")-bisdisulfide

inébilizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')];
dimère (230-230":233-233")-bisdisulfure

inebilizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-451) [VH humanizada (*Homo sapiens* IGHV3-15*06 (83.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV6-21*01 (79.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')];
dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SSWMNWVRQA PGKGLEWVGR  50
IYPGDGDTNY NVKFKGRFTI SRDDSKNSLY LQMNSLKTED TAVYYCARSG 100
FITTVRDFDY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPDF QSVTPKEKVT ITCRASESVD TFGISFMNWF QQKPDQSPKL  50
LIHEASNQGS GVPSRFSGSG SGTDFTLTIN SLEAEDAATY YCQQSKEVPF 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	265-325	371-429
	22"-96"	148"-204"	265"-325"	371"-429"
Intra-L (C23-C104)	23'-92'	138'-198'		
	23'"-92'"	138'"-198'"		
Inter-H-L (h 5-CL 126)	224-218'	224"-218'"		
Inter-H-H (h 11, h 14)	230-230"	233-233"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
301, 301"
Afucosylated complex bi-antennary CHO-type glycans / Glycanes de type CHO bi-antennaires complexes afucosylés / Glicanos de tipo CHO biantenarios complejos no fucosilados

ingenoli disoxas

ingenol disoxate

(1a*R*,2*S*,3*Z*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1*H*-2,8a-methanocyclopenta[*a*]cyclpropa[*e*][10]annulen-6-yl 3,5-diethylisoxazole-4-carboxylate

disoxate d'ingénol	3,5-diéthylisoxazole-4-carboxylate de (1a*R*,2*S*,3*Z*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihydroxy-4-(hydroxyméthyl)-1,1,7,9-tétraméthyl-11-oxo-1a,2,5,5a,6,9,10,10a-octahydro-1*H*-2,8a-méthanocyclopenta[*a*]cyclpropa[*e*][10]annulén-6-yle
disoxato de ingenol	3,5-dietillisoxazol-4-carboxilato de (1a*R*,2*S*,3*Z*,5*R*,5a*S*,6*S*,8a*S*,9*R*,10a*R*)-5,5a-dihidroxi-4-(hidroximetil)-1,1,7,9-tetrametil-11-oxo-1a,2,5,5a,6,9,10,10a-octahidro-1*H*-2,8a-metanociclopenta[*a*]ciclpropa[*e*][10]anulen-6-ilo

$C_{28}H_{37}NO_7$



iodinum (^{131}I) derlotuximabum biotinum #

iodine (^{131}I) derlotuximab biotin	immunoglobulin G1-kappa, anti-[*Homo sapiens* DNA/histone 1 (H1) complex], chimeric monoclonal antibody radiolabeled with iodine-131 and biotinylated; gamma1 heavy chain (1-450) [*Mus musculus* VH (IGHV2-6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-215')-disulfide with kappa light chain (1'-215') [*Mus musculus* V-KAPPA (IGKV4-57-1*01 -IGKJ1*01) [7.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; dimer (229-229":232-232")-bisdisulfide; (^{131}I) iodinatedwith iodine-131 covalently linked to tyrosines, and biotinylated
iodine (^{131}I) derlotuximab biotine	immunoglobuline G1-kappa, anti-[*Homo sapiens* complexe ADN/histone 1 (H1)], anticorps monoclonal chimérique biotinylé et marqué à l'iode 131; chaîne lourde gamma1 (1-450) [*Mus musculus* VH (IGHV2-6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-215')-disulfure avec la chaîne légère kappa (1'-215') [*Mus musculus* V-KAPPA (IGKV4-57-1*01 -IGKJ1*01) [7.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; dimère (229-229":232-232")-bisdisulfure; marqué à l'iode 131 (^{131}I) lié de manière covalente à des tyrosines, et biotinylé

iodo (^{131}I) derlotuximab biotina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* complejo ADN/histona 1 (H1)], anticuerpo monoclonal quimérico biotinilado y marcado con iodo 131;
cadena pesada gamma1 (1-450) [*Mus musculus* VH (IGHV2-6-5*01 -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - *Homo sapiens* IGHG1*01, G1m17,1 (CH1 V121>A (218) (121-218), bisagra(219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-215')-disulfuro con la cadena ligera kappa (1'-215') [*Mus musculus* V-KAPPA (IGKV4-57-1*01 -IGKJ1*01) [7.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (109'-215')]; dímero (229-229'':232-232'')-bisdisulfuro; marcado con iodo 131 (^{131}I) unido covalentemente a tirosinas, y biotinilado

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLKESGPG LVAPSQSLSI TCTVSGFSLT DYGVRWIRQP PGKGLEWLGV  50
IWGGGSTYYN SALKSRLSIS KDNSKSQVFL KMNSLQTDDT AMYYCAKEKR 100
RGYYYAMDYW GQGTSVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKAEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
ENVLTQSPAI MSASPGEKVT MTCRASSSVS SSYLHWYQQK SGASPKLWIY  50
STSNLASGVP ARFSGSGSGT SYSLTISSVE AEDAATYYCQ QYSGYPLTFG 100
GGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	147-203	264-324	370-428
	22''-95''	147''-203''	264''-324''	370''-428''
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L (h 5-CL 126)	223-215'	223''-215'''		
Inter-H-H (h 11, h 14)	229-229''	232-232''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary NS0-type glycans / glycanes de type NS0 bi-antennaires complexes fucosylés / glicanos de tipo NS0 biantenario complejos fucosilados

Modified residues / Résidus modifiés / Restos modificados



isunakinrum #
isunakinra

human interleukin-1 beta-(1-8)-peptide fusion protein with human interleukin-1 receptor antagonist protein-(14-45)-peptide fusion protein with human interleukin-1 beta-(42-120)-peptide fusion protein with human interleukin-1 receptor antagonist protein-(120-147)-peptide fusion protein with human interleukin-1 beta-(148-153)-peptide non-glycosylated

isunakinra

interleukine-1 bêta humaine-(1-8)-peptide protéine de fusion avec l'antagoniste protéique du récepteur de l'interleukine-1 humain-(14-45)-peptide protéine de fusion avec l'interleukine-1 bêta humaine-(42-120)-peptide protéine de fusion avec l'antagoniste protéique du récepteur de l'interleukine-1 humain-(120-147)-peptide protéine de fusion avec l'interleukine-1 bêta humaine-(148-153)-peptide non-glycosylé

isunakinra

interleukina-1 beta humana-(1-8)-péptido proteína de fusión con el antagonista proteíco del receptor de la interleukina-1 humana-(14-45)-péptido proteína de fusión con la interleukina-1 beta humana-(42-120)-péptido proteína de fusión con el antagonista proteíco del receptor de la interleukina-1 humana-(120-147)-péptido proteína de fusión con la interleukina-1 beta humana-(148-153)-péptido no-glicosilado

```
APVRSLNCRI WDVNQKTFYL RNNQLVAGYL QGPNVNLEEK FSMSFVQGEE 50
SNDKIPVALG LKEKNLYLSC VLKDDKPTLQ LESVDPKNYP KKKMEKRFVF 100
NKIEINNKLE FESAQFPNWF LCTAMEADQP VSLTNMPDEG VMVTKFYMQF 150
VSS                                                    153
```

labetuzumabum govitecanum #

labetuzumab govitecan

immunoglobulin G1-kappa, anti-[*Homo sapiens* CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e)], monoclonal antibody conjugated to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan (CPT-11, camptothecin-11), via a maleimide-type cleavable linker (carbonate group, 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8)

labétuzumab govitécan

immunoglobuline G1-kappa, anti-[*Homo sapiens* CEACAM5 (molécule d'adhésion cellulaire 5 apparentée à l'antigène carcinoembryonaire, CEA, CD66e)], anticorps monoclonal conjugué à la 7-éthyl-10-hydroxycamptothécine (SN-38), métabolite actif de l'irinotécan;
chaîne lourde gamma1 (1-449) [humanized VH (*Homo sapiens* IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 6 cystéinyl en moyenne, à la 7-éthyl-10-hydroxycamptothécine (SN-38), métabolite actif de l'irinotécan (CPT-11, camptothécine-11), via un linker de type maléimide, clivable (liaison carbonate, 4-aminobenzyl alcool et dipeptide Phe-Lys clivable par la cathepsine B) et comprenant un groupe triazoline et un espaceur PEG (n=8)

labetuzumab govitecán

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CEACAM5 (molècula de adhesión celular 5 relacionada con el antígeno carcinoembrionario, CEA, CD66e)], anticuerpo monoclonal conjugado con la 7-etil-10-hidroxicamptotecina (SN-38), metabolito activo del irinotecán;
cadena pesada gamma1 (1-449) [humanizado VH (*Homo sapiens* IGHV3-48*01 (75.30%) -(IGHD)-IGHJ5*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.70%) -IGKJ1*01) [6.3.8] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en una media de 6 restos cisteinil, con la 7-etil-10-hidroxicamptotecina (SN-38), metabolito activo del irinotecán (CPT-11, camptotecina-11), mediante un espaciador de tipo maleimida, escindible (enlace carbonato, 4-aminobencil alcohol y dipéptido Phe-Lys escindible por catepsina B) y que comprende un grupo triazolina y un espaciador PEG (n=8)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCSASGFDFT TYWMSWVRQA PGKGLEWIGE  50
IHPDSSTINY APSLKDRFTI SRDNAKNTLF LQMDSLRPED TGVYFCASLY 100
FGFPWFAYWG QGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVT ITCKASQDVG TSVAWYQQKP GKAPKLLIYW  50
TSTRHTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ YSLYRSFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 133'-193'
23'"-88'" 133'"-193'"
Inter-H-L (h 5-CL 126) * 222-213' 222"-213'"
Inter-H-H (h 11, h 14) * 228-228" 231-231"

*Three of the inter-chain disulfide bridges are not present, an average of 6 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Trois des ponts disulfures inter-chaînes ne sont pas présents, 6 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan tres puentes disulfuro inter-catenarios, una media de 6 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

C*
213'-213'"-222-222"-228-228"-231-231"

* an average of 6 are substituted
* en moyenne, 6 sont substitués
* una media de 6 está sustituída



landogrozumabum #

landogrozumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8)], humanized monoclonal antibody;
gamma4 heavy chain (1-439) [humanized VH (*Homo sapiens* IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6] (1-113)) , IGHG4*01 (CH1 (114-211), hinge S10>P (221) (212-223), CH2 (224-333), CH3 (334-438), CHS K2>del (439)) (114-439)], (127-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimer (219-219":222-222")-bisdisulfide

landogrozumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* MSTN (myostatine, facteur de croissance et de différenciation 8, GDF8, GDF-8)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens* IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6] (1-113)) , IGHG4*01 (CH1 (114-211), charnière S10>P (221) (212-223), CH2 (224-333), CH3 (334-438), CHS K2>del (439)) (114-439)], (127-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (219-219":222-222")-bisdisulfure

landogrozumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MSTN (miostatina, factor de crecimiento y de diferenciación 8, GDF8, GDF-8)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-441) [VH humanizado (*Homo sapiens* IGHV3-23*04 (89.80%) -(IGHD)-IGHJ4*01 [8.8.6] (1-113)) , IGHG4*01 (CH1 (114-211),bisagra S10>P (221) (212-223), CH2 (224-333), CH3 (334-438), CHS K2>del (439)) (114-439)], (127-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV3-20*01 (89.10%) -IGKJ4*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (219-219":222-222")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGLTFS RYPMSWVRQA PGKGLVWVSA  50
ITSSGGSTYY SDTVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCARLP 100
DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TKTYTCNVDH 200
KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMISRTP 250
EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT 300
VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE 350
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY 400
SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLG             439
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASSSVS SSYLHWYQQK PGQAPRLLIY  50
STSNLVAGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ HHSGYHFTFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	140-196	254-314	360-418
	22"-96"	140"-196"	254"-314"	360"-418"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	127-215'	127"-215'"		
Inter-H-H (h 8, h 11)	219-219"	222-222"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
290, 290"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

lefitolimodum

lefitolimod

DNA based immunomodulator agent:
cyclo-(3'→5')[2'-deoxy-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G)]

léfitolimod

immunomodulateur de type ADN:
cyclo-(3'→5')[2'-déoxy-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G)]

lefitolimod

inmunomodulador de tipo ADN:
ciclo-(3'→5')[2'-desoxi-(A-A-A-A-C-G-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-T-T-C-G-G-G-G-C-G-T-T-C-T-T-A-G-G-T-G-G-T-A-A-C-C-C-C-T-A-G-G-G-G-T-T-A-C-C-A-C-C-T-T-C-A-T-T-G-G)]



maralixibati chloridum

maralixibat chloride

1-{[4-({4-[(4*R*,5*R*)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1*H*-1λ^6-benzothiepin-5-yl]phenoxy}methyl)phenyl]methyl}-1,4-diazabicyclo[2.2.2]octan-1-ium chloride

chlorure de maralixibat

chlorure de 1-{[4-({4-[(4*R*,5*R*)-3,3-dibutyl-7-(diméthylamino)-4-hydroxy-1,1-dioxo-2,3,4,5-tétrahydro-1*H*-1λ^6-benzothiépin-5-yl]phénoxy}méthyl)phényl]méthyl}-1,4-diazabicyclo[2.2.2]octan-1-ium

cloruro de maralixibat

cloruro de 1-{[4-({4-[(4*R*,5*R*)-3,3-dibutil-7-(dimetilamino)-4-hidroxi-1,1-dioxo-2,3,4,5-tetrahidro-1*H*-1λ^6-benzotiepin-5-il]fenoxi}metil)fenil]metil}-1,4-diazabiciclo[2.2.2]octan-1-io

$C_{40}H_{56}ClN_3O_4S$



marzeptacogum alfa (activatum) #

marzeptacog alfa (activated)

recombinant DNA derived human blood coagulation factor VIIa analogue:
[128-L-asparagine(T>N),129-L-alanine(P>A),286-L-arginine(Q>R),298-L-glutamine(M>Q)]activated human coagulation factor VII (proconvertine, SPCA), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

marzeptacog alfa (activé)

analogue du facteur VIIa de coagulation sanguine humain produit à partir d'ADN recombinant :
[128-L-asparagine(T>N),129-L-alanine(P>A),286-L-arginine(Q>R),298-L-glutamine(M>Q)]facteur VII de coagulation humain activé (proconvertine, SPCA), produite par des cellules ovariennes de hamster chinois (CHO), forme glycosylée alfa

marzeptacog alfa (activado)

análogo del factor VIIa de coagulación sanguínea humano producido a partir de ADN recombinante :
[128-L-asparagina(T>N),129-L-alanina(P>A),286-L-arginina(Q>R),298-L-glutamina(M>Q)]factor VII de coagulación humano activado (proconvertina, SPCA), producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

Light chain / Chaîne légère / Cadena ligera

```
ANAFLEELRP GSLERECKEE QCSFEEAREI FKDAERTKLF WISYSDGDQC 50
ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
YCSDHTGTKR SCRCHEGYSL LADGVSCNAT VEYPCGKIPI LEKRNASKPQ 150
GR                                                    152
```

Heavy chain / Chaîne lourde / Cadena pesada

```
   IVGGKVCP KGECPWQVLL LVNGAQLCGG TLINTIWVVS AAHCFDKIKN 200
WRNLIAVLGE HDLSEHDGDE QSRRVAQVII PSTYVPGTTN HDIALLRLHQ 250
PVVLTDHVVP LCLPERTFSE RTLAFVRFSL VSGWGRLLDR GATALELQVL 300
NVPRLMTQDC LQQSRKVGDS PNITEYMFCA GYSDGSKDSC KGDSGGPHAT 350
HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV SQYIEWLQKL MRSEPRPGVL 400
LRAPFP                                                406
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

17-22 50-61 55-70 72-81 91-102 98-112
114-127 135-262 159-164 178-194 310-329 340-368

Modified residues / Résidus modifiés / Restos modificados



Glycosylation sites (S or N) / Sites de glycosylation (S ou N) / Posiciones de glicosilación (S o N)

Ser-52 Ser-60 Asn-128 Asn-145 Asn-322

mecapegfilgrastimum #

mecapegfilgrastim

[1-[*N*-(3-{[(3*RS*)-1-{3-[(2-{[ω-methoxypoly(oxyethane-1,2-diyl)]formamido}ethyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl]sulfanyl}propyl)-L-methionine]]human granulocyte colony-stimulating factor (pluripoietin) isoform Short

mécapegfilgrastim

[1-[*N*-(3-{[(3*RS*)-1-{3-[(2-{[ω-méthoxypoly(oxyéthane-1,2-diyl)]formamido}éthyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl]sulfanyl}propyl)-L-méthionine]]isoforme court (*Short*) du facteur de stimulation des colonies de granulocytes humain (pluripoiétine)

mecapegfilgrastim

[1-[*N*-(3-{[(3*RS*)-1-{3-[(2-{[ω-metoxipoli(oxietano-1,2-diil)]formamido}etil)amino]-3-oxopropil}-2,5-dioxopirrolidin-3-il]sulfanil}propil)-L-metionina]]isoforma corta (*Short*) del factor humano de estimulación de colonias de granulocitos (pluripoyetina)

Sequence / Séquence / Secuencia

```
MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG 150
GVLVASHLQS FLEVSYRVLR HLAQP   175
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
37-43 65-75

Modified residue / Résidu modifié / Resto modificado



merestinibum

merestinib

N-(3-fluoro-4-{[1-methyl-6-(1*H*-pyrazol-4-yl)-1*H*-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

mérestinib

N-(3-fluoro-4-{[1-méthyl-6-(1*H*-pyrazol-4-yl)-1*H*-indazol-5-yl]oxy}phényl)-1-(4-fluorophényl)-6-méthyl-2-oxo-1,2-dihydropyridine-3-carboxamide

merestinib

N-(3-fluoro-4-{[1-metil-6-(1*H*-pirazol-4-il)-1*H*-indazol-5-il]oxi}fenil)-1-(4-fluorofenil)-6-metil-2-oxo-1,2-dihidropiridina-3-carboxamida

$C_{30}H_{22}F_2N_6O_3$



mirvetuximabum soravtansinum #

mirvetuximab soravtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], chimeric monoclonal antibody conjugated to maytansinoid DM4;

	gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with kappa light chain (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide;conjugated, on an average of 3 or 4 lysyl, to maytansinoid DM4 [*N*2'-deacetyl-*N*2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via the reducible sulfo-SPDB linker [*N*-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate]
mirvétuximab soravtansine	immunoglobuline G1-kappa, anti-[*Homo sapiens* FOLR1 (réceptor 1 du folate, récepteur alpha du folate, FR-alpha, protéine de l'adulte liant le folate, FBP, antigène MOv18 associé à des tumeurs ovariennes)], anticorps monoclonal chimérique conjugué au maytansinoïde DM4; chaîne lourde gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (227-227'':230-230'')-bisdisulfure; conjugué, sur 3 ou 4 lysyl en moyenne, au maytansinoïde DM4 [*N*2'-déacétyl-*N*2'-(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via le linker sulfo-SPDB réductible [4-(2-pyridyldithio)-2-sulfobutanoate de *N*-succinimidyle]
mirvetuximab soravtansina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* FOLR1 (receptor 1 de folato, receptor alfa de folato, FR-alfa, proteína del adulto que liga el folato, FBP, antígeno MOv18 asociado a tumores ováricos)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM4; cadena pesada gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (119-216), cbisagra (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfuro con la cadena ligera-*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (227-227'':230-230'')-bisdisulfuro; conjugado en 3-4 grupos lisil por término medio con el maitansinoide DM4 [*N*2'-desacetil-*N*2'-(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el espaciador sulfo-SPDB reducible [4-(2-piridilditio)butanoato de *N*-succinimidilo]

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VVKPGASVKI SCKASGYTFT GYFMNWVKQS PGQSLEWIGR  50
IHPYDGDTFY NQKFQGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD 100
GSRAMDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPLS LAVSLGQPAI ISCKASQSVS FAGTSLMHWY HQKPGQQPRL  50
LIYRASNLEA GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQQSREYPY 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-92' 138'-198'
23"'-92"' 138"'-198"'
Inter-H-L (h 5-CL 126) 221-218' 221"-218"'
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

soravtansine / soravtansine / soravtansina

$Ig(NH_2)_n$ = Immunoglobulin



monalizumabum #

monalizumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* KLRC1 (killer cell lectin-like receptor subfamily C member 1, NKG2-A, NKG2A, CD159a, CD94)],humanized monoclonal antibody; gamma4 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01 R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) - IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide
monalizumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* KLRC1 (membre 1 de la sous-famille C des récepteurs de type lectine des cellules NK, NKG2-A, NKG2A, CD159a, CD94)], anticorps monoclonal humanisé;

chaîne lourde gamma4 (1-452) [VH humanisé (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01 R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01 (CH1 (126-223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

monalizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* KLRC1 (miembro 1 de la subfamilia C de receptores de tipo lectina de las células NK, NKG2-A, NKG2A, CD159a, CD94)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-452) [VH humanizado (*Homo sapiens* IGHV1-18*01 (89.80%) -(IGHD)-IGHJ2*01 R120>Q (117), L123>T (130)) [8.8.18] (1-125)), IGHG4*01 (CH1 (126-223), bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (126-452)], (139-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMNWVRQA PGQGLEWMGR  50
IDPYDSETHY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARGG 100
YDFDVGTLYW FFDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL 150
GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS 200
LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ 300
FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE 350
PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASENIY SYLAWYQQKP GKAPKLLIYN  50
AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYGTPRTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	152-208	266-326	372-430
	22"-96"	152"-208"	266"-326"	372"-430"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	139-214'	139"-214'"		
Inter-H-H (h 8, h 11)	231-231"	234-234"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

murepavadinum

murepavadin

cyclo[L-alanyl-L-seryl-D-prolyl-L-prolyl-L-threonyl-L-tryptophyl-L-isoleucyl-(2*S*)-2,4-diaminobutanoyl-L-ornithyl-(2*R*)-2,4-diaminobutanoyl-(2*S*)-2,4-diaminobutanoyl-L-tryptophyl-(2*S*)-2,4-diaminobutanoyl-(2*S*)-2,4-diaminobutanoyl]

murépavadine

cyclo[L-alanyl-L-séryl-D-prolyl-L-prolyl-L-thréonyl-L-tryptophyl-L-isoleucyl-(2*S*)-2,4-diaminobutanoyl-L-ornithyl-(2*R*)-2,4-diaminobutanoyl-(2*S*)-2,4-diaminobutanoyl-L-tryptophyl-(2*S*)-2,4-diaminobutanoyl-(2*S*)-2,4-diaminobutanoyl]

murepavadina

ciclo[L-alanil-L-seril-D-prolil-L-prolil-L-treonil-L-triptofil-L-isoleucil-(2*S*)-2,4-diaminobutanoil-L-ornitil-(2*R*)-2,4-diaminobutanoil-(2*S*)-2,4-diaminobutanoil-L-triptofil-(2*S*)-2,4-diaminobutanoil-(2*S*)-2,4-diaminobutanoil]

$C_{73}H_{112}N_{22}O_{16}$



nadorameranum #

nadorameran

an mRNA molecule encoding the rabies virus glycoprotein RAV-G containing elements for expression within eukaryotic cells; manufactured by enzymatic *in vitro* transcription from linearized plasmid DNA

nadoraméran

ARN messager codant la glycoprotéine G du virus de la rage contenant les éléments pour son expression dans des cellules eucaryotes; obtenu par transcription enzymatique *in vitro* à partir d'ADN de plasmide linéarisé

nadoramerán

ARN mensajero que codifica la glicoproteína G del virus de la rabia y contiene los elementos para su expresión en células eucariotas; obtenido por transcripción enzimática *in vitro* a partir de ADN de plásmido transformado en lineal

nastorazepidum

nastorazepide

3-({[(3*R*)-5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-2,3,4,5-tetrahydro-1*H*-1,5-benzodiazepin-3-yl]carbamoyl}amino)benzoic acid

nastorazépide

acide 3-({[(3*R*)-5-cyclohexyl-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-2,3,4,5-tétrahydro-1*H*-1,5-benzodiazépin-3-yl]carbamoyl}amino)benzoïque

nastorazepida

ácido 3-({[(3*R*)-5-ciclohexyl-1-(3,3-dimetil-2-oxobutil)-2-oxo-2,3,4,5-tetrahidro-1*H*-1,5-benzodiazepin-3-il]carbamoil}amino)benzoico

$C_{29}H_{36}N_4O_5$



natrii cinhyaluronas

cinhyaluronate sodium

sodium salt of hyaluronic acid partly amidified with 3-{[(2*E*)-3-phenylprop-2-enoyl]oxy}propan-1-amine

cinhyaluronate de sodium

sel sodique de l'acide hyaluronique partiellement amidifié par la 3-{[(2*E*)-3-phénylprop-2-énoyl]oxy}propan-1-amine

cinhialuronato de sodio

sal sódica del ácido hialurónico parcialmente amidificado por la 3-{[(2*E*)-3-fenilprop-2-enoil]oxi}propan-1-amina

$[(C_{26}H_{34}N_2O_{12})_a(C_{14}H_{20}NNaO_{11})_b]_nH_2O$



navivumabum #

navivumab

immunoglobulin G1-kappa, anti-[influenza A virus hemagglutinin HA], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV1-18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -IGHG1*07, G1m17,1,2 (CH1 (127-224), hinge (225-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (82.30%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (235-235'':238-238'')-bisdisulfide

navivumab

immunoglobuline G1-kappa, anti-[hémagglutinine HA du virus de la grippe A], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV1-18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -IGHG1*07, G1m17,1,2 (CH1 (127-224), charnière (225-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (82.30%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (235-235'':238-238'')-bisdisulfure

navivumab

inmunoglobulina G1-kappa, anti-[hemaglutinina HA del virus de la gripe A], anticuerpo monoclonal *Homo sapiens*; cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV1-18*01 (78.60%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -IGHG1*07, G1m17,1,2 (CH1 (127-224), bisagra (225-239), CH2 (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (82.30%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dímero (235-235'':238-238'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKTSGYSFS TYGVSWVRQA PGQGPEWVGW  50
ISAYTGITDY AQKFQGRVTL TTDATTATAF LDLRSLRPDD TATYFCARDK 100
VQGRVEVGSG GRHDYWGQGT LVIVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEG LHNHYTQKSL 450
SLSPGK                                                 456
```

Light chain / Chaîne légère / Cadena ligera

```
EVVLTQSPGT LALPPGERAT LSCRASHRVG STYIAWYQQK SGQAPRRLIY  50
GASNRATDIP DRFSGSGSGT DFTLTIRRLE PEDSAVYYCQ QFSVSPWTFG 100
QGTRVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	153-209	270-330	376-434
	22"-96"	153"-209"	270"-330"	376"-434"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	229-215'	229"-215'"		
Inter-H-H (h 11, h 14)	235-235"	238-238"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
306, 306"

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
456, 456"

neladenosoni bialanas

neladenoson bialanate

2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl L-alanyl-L-alaninate

bialanate de néladénoson

L-alanyl-L-alaninate de 2-{4-[2-({[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phénoxy}éthyle

bialanato de neladenosón

L-alanil-L-alaninato de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridin-4-il]fenoxi}etilo

$C_{35}H_{34}ClN_7O_4S_2$



netarsudilum

netarsudil — {4-[(2*S*)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl}methyl 2,4-dimethylbenzoate

nétarsudil — 2,4-diméthylbenzoate de {4-[(2*S*)-3-amino-1-(isoquinoléin-6-ylamino)-1-oxopropan-2-yl]phényl}méthyle

netarsudil — 2,4-dimetilbenzoato de {4-[(2*S*)-3-amino-1-(isoquinolein-6-ilamino)-1-oxopropan-2-il]fenil}metilo

$C_{28}H_{27}N_3O_3$



obiltoxaximabum #

obiltoxaximab — immunoglobulin G1-kappa, anti-[*Bacillus anthracis* anthrax toxin protective antigen (PA)], chimeric monoclonal antibody;
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-82*01 -(IGHD)-*Homo sapiens* IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -*Homo sapiens* IGKJ1*01 K127>R (107) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

obiltoxaximab — immunoglobuline G1-kappa, anti-[antigène protecteur (AP) de la toxine de *Bacillus anthracis* de la maladie du charbon], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-82*01 -(IGHD)-*Homo sapiens* IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -*Homo sapiens* IGKJ1*01 K127>R (107) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

obiltoxaximab — inmunoglobulina G1-kappa, anti-[antigeno protector (AP) de la toxina de *Bacillus anthracis*, del carbunco], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-82*01 -(IGHD)-*Homo sapiens* IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -*Homo sapiens* IGKJ1*01 K127>R (107) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPE LKKPGASVKV SCKDSGYAFS SSWMNWVRQA PGQGLEWIGR  50
IYPGDGDTNY NGKFQGRVTI TADKSSSTAY MELSSLRSED TAVYFCARSG 100
LLRYAMDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIR NYLNWYQQKP GKAVKLLIYY  50
TSRLLPGVPS RFSGSGSGTD YSLTISSQEQ EDIGTYFCQQ GNTLPWTFGQ 100
GTKVEIRRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 222-214' 222"-214'"
Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"

omaveloxolonum

omaveloxolone — *N*-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide

omavéloxolone — *N*-(2-cyano-3,12-dioxo-28-noroléana-1,9(11)-dién-17-yl)-2,2-difluoropropanamide

omaveloxolona — *N*-(2-ciano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-il)-2,2-difluoropropanamida

$C_{33}H_{44}F_2N_2O_3$



opicinumabum #

opicinumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* LINGO1 (leucine-rich repeat and Ig-like domain-containing nogo receptor-interacting protein 1, LINGO-1, leucine-rich repeat neuronal protein 1, LERN1, leucine-rich repeat neuronal protein 6A, LRRN6A)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-118) -IGHG1*01, G1m17,1 (CH1 (119-216), hinge (217-231), CH2 T85.3>A (300) (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (227-227":230-230")-bisdisulfide

opicinumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* LINGO1 (protéine 1 interagissant avec le récepteur de nogo et contenant des répétitions riches en leucine et un domaine Ig-like, LINGO-1, protéine neuronale 1 contenant des répétitions riches en leucine, LERN1, protéine neuronale 6A contenant des répétitions riches en leucine, LRRN6A)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV3-23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-118) -IGHG1*01, G1m17,1 (CH1 (119-216), charnière (217-231), CH2 T85.3>A (300) (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (227-227":230-230")-bisdisulfure

opicinumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* LINGO1 (proteína 1 que interacciona con el receptor de nogo y contiene repeticiones ricas en leucina y un dominio Ig-like, LINGO-1, proteína neuronal 1, que contiene repeticiones ricas en leucina,LERN1, proteína neuronal 6A que contiene repeticiones ricas en leucina, LRRN6A)], anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV3-23*01 (91.80%) -(IGHD)-IGHJ3*02) [8.8.11] (1-118) -IGHG1*01, G1m17,1 (CH1 (119-216), bisagra (217-231), CH2 T85.3>A (300) (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (96.80%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS AYEMKWVRQA PGKGLEWVSV  50
IGPSGGFTFY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCATEG 100
DNDAFDIWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNSA 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPMYTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-88'	135'-195'		
	23'"-88'"	135'"-195'"		
Inter-H-L (h 5-CL 126)	221-215'	221"-215'"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298" but no glycosylation owing to / mais pas de glycosylation dû à / pero ningún glicosilación debida a H CH2 T85.3>A (300, 300")

osimertinibum

osimertinib	*N*-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1*H*-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
osimertinib	*N*-(2-{[2-(diméthylamino)éthyl](méthyl)amino}-4-méthoxy-5-{[4-(1-méthyl-1*H*-indol-3-yl)pyrimidin-2-yl]amino}phényl)prop-2-énamide
osimertinib	*N*-(2-{[2-(dimetilamino)etil](metil)amino}-4-metoxi-5-{[4-(1-metil-1*H*-indol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida

$C_{28}H_{33}N_7O_2$



pamrevlumabum #

pamrevlumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CTGF (connective tissue growth factor, CCN family member 2, CCN2, hypertrophic chondrocyte-specific protein 24, HCS24, insulin-like growth factor-binding protein 8, IGFBP-8)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG1*03, G1m3 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer(229-229'':232-232'')-bisdisulfide
pamrevlumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CTGF (facteur de croissance du tissu conjonctif, membre 2 de la famille CCN, CCN2, protéine 24 spécifique de l'hypertrophie des chondrocytes, HCS24, protéine 8 liant le facteur de croissance analogue à l'insuline, IGFBP-8)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV3-48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG1*03, G1m3 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure

pamrevlumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CTGF (factor de crecimiento de tejido conjunctivo, miembro 2 de la familia CCN, CCN2, proteína 24 específica de la hipertrofia de condrocitos, HCS24, proteína 8 que ligada el factor de crecimiento análogo a la insulina, IGFBP-8)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV3-48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) -IGHG1*03, G1m3 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (100.00%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EGQLVQSGGG LVHPGGSLRL SCAGSGFTFS SYGMHWVRQA PGKGLEWVSG  50
IGTGGGTYST DSVKGRFTIS RDNAKNSLYL QMNSLRAEDM AVYYCARGDY 100
YGSGSFFDCW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIS SWLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPPTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	147-203	264-324	370-428
	22''-95''	147''-203''	264''-324''	370''-428''
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	223-214'	223''-214'''		
Inter-H-H (h 11, h 14)	229-229''	232-232''		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary CHO-type glycans/ glycanes de type CHO bi-antennaires complexes fucosylés/ glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H VH CDR3 C117 (109, 109''): cysteinylation with either Cys, Cys-Gly, glutathione, or no cysteinylation
cystéinylation avec soit Cys, Cys-Gly, glutathion, ou absence de cystéinylation / cisteinilación con Cis, o Cis-Gli, o glutatión, o ausencia de cisteinilación

pegcantratinibum

pegcantratinib

(5'*R*,9*S*,12*R*)-9-methyl-3'-[α-methylpoly(oxyethane-1,2-diyl)]-2,3,11,12-tetrahydro-1*H*,9*H*-spiro[9,12-epoxydiindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*i*][1,6]benzodiazocine-10,5'-oxazolidine]-1,2',4'-trione

pegcantratinib

(5'*R*,9*S*,12*R*)-9-méthyl-3'-[α-méthylpoly(oxyéthane-1,2-diyl)]-2,3,11,12-tétrahydro-1*H*,9*H*-spiro[9,12-époxydiindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*i*][1,6]benzodiazocine-10,5'-oxazolidine]-1,2',4'-trione

pegcantratinib

(5'*R*,9*S*,12*R*)-9-metil-3'-[α-metilpoli(oxietano-1,2-diil)]-2,3,11,12-tetrahidro-1*H*,9*H*-espiro[9,12-epoxidiindolo[1,2,3-*fg*:3',2',1'-*kl*]pirrolo[3,4-*i*][1,6]benzodiazocina-10,5'-oxazolidina]-1,2',4'-triona

$C_{28}H_{20}N_4O_5[C_2H_4O]_n$



pemafibratum

pemafibrate	(2*R*)-2-[3-({(1,3-benzoxazol-2-yl)[3-(4-methoxyphenoxy) propyl]amino}methyl)phenoxy]butanoic acid
pémafibrate	acide (2*R*)-2-[3-({(1,3-benzoxazol-2-yl)[3-(4-méthoxyphénoxy)propyl]amino}méthyl)phénoxy] butanoïque
pemafibrato	ácido (2*R*)-2-[3-({(benzoxazol-2-il)[3-(4-metoxifenoxi) propil]amino}metil)fenoxi]butanoico

$C_{28}H_{30}N_2O_6$



piclidenosonum

piclidenoson	1-deoxy-1-(6-{[(3-iodophenyl)methyl]amino}-9*H*-purin-9-yl)-*N*-methyl-β-D-ribofuranuronamide
piclidénoson	1-déoxy-1-(6-{[(3-iodophényl)méthyl]amino}-9*H*-purin-9-yl)-*N*-méthyl-β-D-ribofuranuronamide
piclidenosón	1-desoxi-1-(6-{[(3-iodofenil)metil]amino}-9*H*-purin-9-il)-*N*-metil-β-D-ribofuranuronamida

$C_{18}H_{19}IN_6O_4$



plozalizumabum #

plozalizumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CCR2 (chemokine (C-C motif) receptor 2, C-C chemokine receptor 2, CC-CKR-2, CKR-2, monocyte chemoattractant protein 1 receptor, MCP-1-R, CD192)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01) [8.10.8] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), hinge (216-230), CH2 L1.2>A (235), G1>A (237) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimer (226-226":229-229")-bisdisulfide
plozalizumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CCR2 (récepteur 2 de chimiokine (C-C motif), récepteur 2 de chimiokine C-C, CC-CKR-2, CKR-2, récepteur de la protéine 1 chimio-attractive du monocyte, MCP-1-R, CD192)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01) [8.10.8] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), charnière (216-230), CH2 L1.2>A (235), G1>A (237) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure
plozalizumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CCR2 (receptor 2 de quimiokina (C-C motif), receptor 2 de quimiokina C-C, CC-CKR-2, CKR-2, receptor de la proteína 1 quimioatrayente de monocitos, MCP-1-R, CD192)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizada (*Homo sapiens* IGHV3-73*01 (86.90%) -(IGHD)-IGHJ1*01) [8.10.8] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), bisagra (216-230), CH2 L1.2>A (235), G1>A (237) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVKPGGSLRL SCAASGFTFS AYAMNWVRQA PGKGLEWVGR  50
IRTKNNNYAT YYADSVKDRF TISRDDSKNT LYLQMNSLKT EDTAVYYCTT 100
FYGNGVWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELAGAPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL DSDGKTFLNW FQQRPGQSPR  50
RLIYLVSKLD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCWQGTHFP 100
YTFGQGTRLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	144-200	261-321	367-425
	22"-98"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-93'	139'-199'		
	23'"-93'"	139'"-199'"		
Inter-H-L (h 5-CL 126)	220-219'	220"-219'"		
Inter-H-H (h 11, h 14)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ravidasvirum

ravidasvir — methyl *N*-[(2*S*)-1-{(2*S*)-2-[5-(6-{2-[(2*S*)-1-{(2*S*)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1*H*-imidazol-4-yl}naphthalen-2-yl)-1*H*-benzimidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate

ravidasvir — *N*-[(2*S*)-1-{(2*S*)-2-[5-(6-{2-[(2*S*)-1-{(2*S*)-2-[(méthoxycarbonyl)amino]-3-méthylbutanoyl}pyrrolidin-2-yl]-1*H*-imidazol-4-yl}naphtalén-2-yl)-1*H*-benzimidazol-2-yl]pyrrolidin-1-yl}-3-méthyl-1-oxobutan-2-yl]carbamate de méthyle

ravidasvir — *N*-[(2*S*)-1-{(2*S*)-2-[5-(6-{2-[(2*S*)-1-{(2*S*)-2-[(metoxicarbonil)amino]-3-metilbutanoil}pirrolidin-2-il]-1*H*-imidazol-4-il}naftalen-2-il)-1*H*-benzoimidazol-2-il]pirrolidin-1-il}-3-metil-1-oxobutan-2-il]carbamato de metilo

$C_{42}H_{50}N_8O_6$



rinucumabum #

rinucumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* PDGFRB (platelet-derived growth factor receptor beta subunit, PDGFR-1, CD140b)], human monoclonal antibody; gamma4 heavy chain (1-449) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-122) -IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* (V-KAPPA (IGKV3-20*01 (91.70%) -IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (228-228":231-231")-bisdisulfide

rinucumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* PDGFRB (sous-unité bêta du récepteur du facteur de croissance dérivé des plaquettes, PDGFR-1, CD140b)], anticorps monoclonal humain;
chaîne lourde gamma4 (1-449) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-122) -IGHG4*01 (CH1 (123-220), charnière S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (123-449)], (136-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* (V-KAPPA (IGKV3-20*01 (91.70%) -IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dimère (228-228":231-231")-bisdisulfure

rinucumab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDGFRB (subunidad beta del receptor del factor de crecimiento derivado de plaquetas, PDGFR-1, CD140b)], anticuerpo monoclonal humano;
cadena pesada gamma4 (1-449) [*Homo sapiens* VH (IGHV4-39*01 (92.90%) -(IGHD)-IGHJ5*01) [10.7.14] (1-122) -IGHG4*01 (CH1 (123-220), bisagra S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449) (123-449)], (136-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* (V-KAPPA (IGKV3-20*01 (91.70%) -IGKJ3*01) [7.3.9] (1'-108') -IGKC*01, Km3 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QLQLQESGPG LVKPSETLSL TCTVSGGSIT SSSYYWGWIR QPPGKGLEWI  50
GSIYYRGSTN YNPSLKSRVT ISVDSSKNQF YLKVSSVTAV DTAVYYCARQ 100
NGAARPSWFD PWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
KTYTCNVDHK PSNTKVDKRV ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPDT ISLSPGERAT LSCRASQSIS SIYLAWYQQK PGQAPRLLIY  50
GASSRVTGIP DRFSVSGSGT DFTLTISRLE PEDFAVYYCQ HYGISPFTFG 100
PGTKVDIRRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-97	149-205	263-323	369-427
	22"-97"	149"-205"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-89'	135'-195'		
	23'"-89'"	135'"-195'"		
Inter-H-L (CH1 10-CL 126)	136-215'	136"-215'"		
Inter-H-H (h 8, h 11)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
449, 449"

risankizumabum #

risankizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL23 subunit p19, IL23p19)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (121-218), hinge (219-233), CH2 L1.3>A (237), L1.2>A (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-27*01 (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (229-229":232-232")-bisdisulfide

risankizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL23 sous-unité p19, IL23p19)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (121-218), charnière (219-233), CH2 L1.3>A (237), L1.2>A (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-27*01 (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

risankizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL23 subunidad p19, IL23p19)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-69*02 (79.40%) -(IGHD)-IGHJ5*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (121-218), bisagra (219-233), CH2 L1.3>A (237), L1.2>A (238) (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-27*01 (80.00%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DQTIHWMRQA PGQGLEWIGY  50
IYPRDDSPKY NENFKGKVTI TADKSTSTAY MELSSLRSED TAVYYCAIPD 100
RSGYAWFIYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASRDVA IAVAWYQQKP GKVPKLLIYW  50
ASTRHTGVPS RFSGSGSRTD FTLTISSLQP EDVADYFCHQ YSSYPFTFGS 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	264-324	370-428
	22"-96"	147"-203"	264"-324"	370"-428"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)	223-214'	223"-214'"		
Inter-H-H (h 11, h 14)	229-229"	232-232"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

rivabazumabum pegolum #

rivabazumab pegol	immunoglobulin Fab' G1-kappa pegylated, anti-[*Pseudomonas aeruginosa* type III secretion system (TTSS) PcrV protein], pegylated humanized monoclonal antibody; gamma1 heavy chain fragment VH-(CH1-hinge) (1-238) [humanized VH (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237), CH2 (238)) (125-238)], noncovalently associated with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]; conjugated via a linker of the maleimide group (thioether bond with cysteinyl H h 11 (C233) and H h 14 (236)) to two linear chains of methoxy polyethylene glycol 30 (mPEG30).
rivabazumab pégol	immunoglobuline Fab' G1-kappa pégylé, anti-[protéine PcrV du système de sécrétion type III (TTSS) de *Pseudomonas aeruginosa*], anticorps monoclonal humanisé pégylé; fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-238) [VH humanisé (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), charnière C5>S (227) (223-237), CH2 (238)) (125-238)], associé de manière non covalente avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]; conjugué via un linker du groupe maléimide (liaison thioéther avec les cystéinyl H h 11 (C233) et H h 14 (C236)) à deux chaînes linéaires de méthoxy polyéthylène glycol 30 (mPEG30).
rivabazumab pegol	inmunoglobulina Fab' G1-kappa pegilada, anti-[proteína PcrV del sistema de secreción tipo III (TTSS) de *Pseudomonas aeruginosa*], anticuerpo monoclonal humanizado pegilado; fragmento VH-(CH1-bisagra) de la cadena ligera gamma1 (1-238) [VH humanizado (*Homo sapiens* IGHV3-30*06 (92.90%) -(IGHD)-IGHJ6*01) [8.8.117] (1-124) -*Homo sapiens* IGHG1*01 (CH1(125-222), bisagra C5>S (227) (223-237), CH2 (238)) (125-238)], asociado de modo no covalente con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]; conjugado mediante un espaciador del grupo maleimida (unión tioéter con los cisteinil H h 11 (C233) et H h 14 (C236)) con dos cadenas lineales de metoxi polietilen glicol 30 (mPEG30).

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCAASGFTFS NYPMHWVRQA PGKGLEWVAV  50
ISYDGSEKWY ADSVKGRFTI SRDNSKNTLY LEMNSLRPED TAVYYCARNR 100
GDIYYDFTYA MDIWGQGTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSSDKT HTCPPCPA              238
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPST LSASVGDSVT ITCRASEGVD RWLAWYQQKP GRAPKLLIYD  50
ASTLQSGVPS RFSGSGSGTE FSLTISSLQP DDVATYYCQH FWGTPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGES                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 151-207
Intra-L (C23-C104) 23'-88' 134'-194'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None

Pegylation site / Site de pegylation / Posiciones de pegilación
H hinge h 11, h 14
C233, C236

ronopterinum

ronopterin — (1*R*,2*S*)-1-[(6*RS*)-2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl]propane-1,2-diol

ronoptérine — (1*R*,2*S*)-1-[(6*RS*)-2,4-diamino-5,6,7,8-tétrahydroptéridin-6-yl]propane-1,2-diol

ronopterina — (1*R*,2*S*)-1-[(6*RS*)-2,4-diamino-5,6,7,8-tetrahidropteridin-6-il]propano-1,2-diol

$C_9H_{16}N_6O_2$



and epimer at C*
et l'épimère en C*
y el epímero al C*

rovalpituzumabum #

rovalpituzumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligand 3)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (227-227":230-230")-bisdisulfide

rovalpituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligand 3)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

rovalpituzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligando 3)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 (119-216), bisagra(217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW  50
INTYTGEPTY ADDFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARIG 100
DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCKASQSVS NDVVWYQQKP GQAPRLLIYY  50
ASNRYTGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ DYTSPWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 221-214' 221"-214'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

rovalpituzumabum tesirinum #

rovalpituzumab tesirine	immunoglobulin G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligand 3)], humanized monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (227-227":230-230")-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsin B cleavage site) maleimide type linker containing a spacer PEG (n=8)
rovalpituzumab tésirine	immunoglobuline G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligand 3)], anticorps monoclonal humanisé conjugué au dimère de pyrrolobenzodiazépine (PDB) SCX; chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8)
rovalpituzumab tesirina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* DLL3 (delta-like ligando 3)], anticuerpo monoclonal humanizado conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV1-18*01 (86.700%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 (119-216), bisagra(217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV3-15*01 (87.40%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro; conjugado, en una media de 2 cisteinas, al dímero de pirrolobenzodiazepina (PBD) SCX, mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida que comprende un espaciador PEG (n=8)

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW  50
INTYTGEPTY ADDFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARIG 100
DSSPSDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG    447
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCKASQSVS NDVVWYQQKP GQAPRLLIYY  50
ASNRYTGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ DYTSPWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	145-201	262-322	368-426
	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (h 5-CL 126)*	221-214'	221"-214'"		
Inter-H-H (h 11, h 14)*	227-227"	230-230"		

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan uno o dos puentes disulfuro inter-catenarios, una media de 2 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / Résidus modifies potentiels / Restos modificados potenciales

C 214',214'" ; 221,221" ; 227,227" ; 230,230" "*S*-tesirine Cysteine"



sacituzumabum govitecanum #
sacituzumab govitecan

immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody conjugated to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan;
gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (230-230":233-233")-bisdisulfide; conjugated, on an average of 6 cysteinyl, to 7-ethyl-10-hydroxycamptothecin (SN-38), active metabolite of irinotecan (CPT-11, camptothecin-11),via a maleimide-type cleavable linker (carbonate group, self-immolative 4-aminobenzyl alcohol and cathepsine-B-cleavable dipeptide Phe-Lys) and containing a triazoline group and a spacer PEG (n=8).

sacituzumab govitecan	immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé conjugué à la 7-éthyl-10-hydroxycamptothécine (SN-38), métabolite actif de l'irinotécan; chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (230-230":233-233")-bisdisulfure; conjugué, sur 6 cystéinyl en moyenne, à la 7-éthyl-10-hydroxycamptothécine (SN-38), métabolite actif de l'irinotécan (CPT-11, camptothécine-11),via un linker de type maléimide, clivable (liaison carbonate et 4-aminobenzyl alcool et dipeptide Phe-Lys clivable par la cathepsine B) et comprenant un groupe triazoline et un espaceur PEG (n=8)
sacituzumab govitecán	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales de calcio asociado a los tumores, componente de membrana del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a tumores gastrointestinales, proteína GA733-1 marcador de carcinomes pancreáticos glicoproteína epitelial 1, EGP-1, antígeno 2 de trofoblasto, glicoproteína Trop-2 de la superficie celular, TROP2)], anticuerpo monoclonal humanizado conjugado con la 7-etil-10-hidroxicamptotecina (SN-38), metabolito activo del irinotecán; cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (122-219), bisagra(220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro; conjugado, en una media de 6 restos cisteinil, con la 7-etil-10-hidroxicamptotecina (SN-38), metabolito activo del irinotecán (CPT-11, camptotecina-11), mediante un espaciadorde tipo maleimida, escindible (enlace carbonato y 4-aminobencil alcohol y dipéptido Phe-Lys escindible por catepsina B) y que comprende un grupo triazolina y un espaciador PEG (n=8).

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGSE LKKPGASVKV SCKASGYTFT NYGMNWVKQA PGQGLKWMGW  50
INTYTGEPTY TDDFKGRFAF SLDTSVSTAY LQISSLKADD TAVYFCARGG 100
FGSSYWYFDV WGQGSLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVS ITCKASQDVS IAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPD RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGA 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) * 224-214' 224"-214'"
Inter-H-H (h 11, h 14) * 230-230" 233-233"

*Three of the inter-chain disulfide bridges are not present, an average of 6 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Trois des ponts disulfures inter-chaînes ne sont pas présents, 6 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan tres puentes disulfuro inter-catenarios, una media de 6 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

C*

214'-214'"-224-224"-
230-230"-233-233'"

* an average of 6 are substituted
* en moyenne, 6 sont substitués
* una media de 6 está sustituida



sacubitrilatum

sacubitrilat — (2*R*,4*S*)-5-([1,1'-biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid

sacubitrilate — acide (2*R*,4*S*)-5-([1,1'-biphényl]-4-yl)-4-(3-carboxypropanamido)-2-méthylpentanoïque

sacubitrilat — ácido (2*R*,4*S*)-5-([1,1'-bifenil]-4-il)-4-(3-carboxipropanamido)-2-metilpentanoico

$C_{22}H_{25}NO_5$



selonsertibum

selonsertib — 5-(4-cyclopropyl-1*H*-imidazol-1-yl)-2-fluoro-4-methyl-*N*-{6-[4-(propan-2-yl)-4*H*-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide

sélonsertib — 5-(4-cyclopropyl-1*H*-imidazol-1-yl)-2-fluoro-4-méthyl-*N*-{6-[4-(propan-2-yl)-4*H*-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide

selonsertib — 5-(4-ciclopropil-1*H*-imidazol-1-il)-2-fluoro-4-metil-*N*-{6-[4-(propan-2-il)-4*H*-1,2,4-triazol-3-il]piridin-2-yl}benzamida

$C_{24}H_{24}FN_7O$



solnatidum

solnatide — L-cysteinylglycyl-[human tumor necrosis factor, membrane form-(178-191)-peptidyl]-L-cysteine, cyclic (1→17)-disulfide
or
L-cysteinylglycyl-[human tumor necrosis factor, soluble form-(102-115)-peptidyl]-L-cysteine, cyclic (1→17)-disulfide

solnatide — (1→17)-disulfure cyclique de L-cystéinylglycyl-[forme membranaire du facteur de nécrose tumorale humain-(178-191)-peptidyl]-L-cystéine
ou
(1→17)-disulfure cyclique de L-cystéinylglycyl-[forme soluble du facteur de nécrose tumorale humain-(102-115)-peptidyl]-L-cystéine

solnatida — (1→17)-disulfuro cíclico de L-cisteinilglicil-[forma de membrana del factor de necrosis tumoral humano-(178-191)-peptidil]-L-cisteina
o
(1→17)-disulfuro cíclico de L-cisteinilglicil-[forma soluble del factor de necrosis tumoral humano-(102-115)-peptidil]-L-cisteina

$C_{82}H_{119}N_{23}O_{27}S_2$



sparsentanum

sparsentan — 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-*N*-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[1,1'-biphenyl]-2-sulfonamide

sparsentan — 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-én-3-yl)méthyl]-*N*-(4,5-diméthyl-1,2-oxazol-3-yl)-2'-(éthoxyméthyl)[1,1'-biphényle]-2-sulfonamide

esparsentán — 4'-[(2-butil-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-il)metil]-*N*-(4,5-dimetil-1,2-oxazol-3-il)-2'-(etoximetil)[1,1'-bifenilo]-2-sulfonamida

$C_{32}H_{40}N_4O_5S$



tavilermidum

tavilermide — 3-{(4*S*,7*S*,10*S*)-7-(4-aminobutyl)-4-[(carboxymethyl)carbamoyl]-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahydro-2*H*-1,5,8,11-benzoxatriazacyclotetradecin-10-yl}propanoic acid

tavilermide — acide 3-{(4*S*,7*S*,10*S*)-7-(4-aminobutyl)-4-[(carboxyméthyl)carbamoyl]-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-décahydro-2*H*-1,5,8,11-benzoxatriazacyclotétradécin-10-yl}propanoïque

tavilermida — ácido 3-{(4*S*,7*S*,10*S*)-7-(4-aminobutil)-4-[(carboximetil)carbamoil]-14-nitro-6,9,12-trioxo-3,4,5,6,7,8,9,10,11,12-decahidro-2*H*-1,5,8,11-benzoxatriazaciclotetradecin-10-il}propanoico

$C_{24}H_{32}N_6O_{11}$



tegoprazanum

tegoprazan — 7-{[(4*S*)-5,7-difluoro-3,4-dihydro-2*H*-1-benzopyran-4-yl]oxy}-*N*,*N*,2-trimethyl-1*H*-benzimidazole-5-carboxamide

tégoprazan — 7-{[(4*S*)-5,7-difluoro-3,4-dihydro-2*H*-1-benzopyran-4-yl]oxy}-*N*,*N*,2-triméthyl-1*H*-benzimidazole-5-carboxamide

tegoprazán

7-{[(4*S*)-5,7-difluoro-3,4-dihidro-2*H*-1-benzopiran-4-il]oxi}-*N*,*N*,2-trimetil-1*H*-benzoimidazol-5-carboxamida

$C_{20}H_{19}F_2N_3O_3$



tesevatinibum

tesevatinib

N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-{[(3a*R*,5*r*,6a*S*)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methoxy}quinazolin-4-amine

tésévatinib

N-(3,4-dichloro-2-fluorophényl)-6-méthoxy-7-{[(3a*R*,5*r*,6a*S*)-2-méthyloctahydrocyclopenta[*c*]pyrrol-5-yl]méthoxy}quinazolin-4-amine

tesevatinib

N-(3,4-dicloro-2-fluorofenil)- 7-{[(3a*R*,5*r*,6a*S*)-2-metiloctahidrociclopenta[*c*]pirrol-5-il]metoxi}-6-metoxi-quinazolin-4-amina

$C_{24}H_{25}Cl_2FN_4O_2$



tezepelumabum #

tezepelumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* TSLP (thymic stromal lymphopoietin)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG2*01, G2m.. (CH1 (123-220), hinge (221-232), CH2 (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*02 (96.90%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

tézépelumab	immunoglobuline G2-lambda, anti-[*Homo sapiens* TSLP (lymphopoïétine stromale thymique)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-448) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG2*01, G2m.. (CH1 (123-220), charnière (221-232), CH2 (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*02 (96.90%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (224-224'':225-225'':228-228'':231-231'')-tétrakisdisulfure
tezepelumab	inmunoglobulina G2-lambda, anti-[*Homo sapiens* TSLP (linfopoyetina estromal tímica)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-448) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ3*02) [8.8.15] (1-122) -IGHG2*01, G2m.. (CH1 (123-220),bisagra (221-232), CH2 (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-21*02 (96.90%) -IGLJ2*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (224-224'':225-225'':228-228'':231-231'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QMQLVESGGG VVQPGRSLRL SCAASGFTFR TYGMHWVRQA PGKGLEWVAV  50
IWYDGSNKHY ADSVKGRFTI TRDNSKNTLN LQMNSLRAED TAVYYCARAP 100
QWELVHEAFD IWGQGTMVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSNFGT 200
QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP APIEKTISKT KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
SYVLTQPPSV SVAPGQTARI TCGGNNLGSK SVHWYQQKPG QAPVLVVYDD  50
SDRPSWIPER FSGSNSGNTA TLTISRGEAG DEADYYCQVW DSSSDHVVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 262-322 368-426
22"-96" 149"-205" 262"-322" 368"-426"
Intra-L (C23-C104) 22'-87' 136'-195'
22'"-87'" 136'"-195'"
Inter-H-L (CH1 10-CL 126) 136-213' 136"-213'"
Inter-H-H (h 4, h 5, h 8, h 11) 224-224" 225-225" 228-228" 231-231"

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 224-136" and an inter-H-L (h 4- CL 126) 224"-213'", instead of the inter-H-H (h 4 - h 4) 224-224" and of one of the two inter-H-L (CH1 10-CL 126) 136"-213'".

*En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 224-136" et un inter-H-L (h 4- CL 126) 224"-213'", au lieu de l'inter-H-H (h 4 - h 4) 224-224" et de l'un des deux inter-H-L (CH1 10-CL 126) 136"-213'".

* además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h 4 - CH1 10) 224-136" y un inter-H-L (h 4- CL 126) 224"-213'", en lugar del inter-H-H (h 4 - h 4) 224-224" y uno de los dos inter-H-L (CH1 10-CL 126) 136"-213'".

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de typeCHO bi-antennaires complexes fucosylés / glicanosde tipo CHO biantenarios complejos fucosilados

tisotumabum # tisotumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* F3 (coagulation factor III (thromboplastin, tissue factor), CD142)], *Homo sapiens* monoclonal antibody;

	gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide
tisotumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* F3 (facteur de coagulation III (thromboplastine, facteur tissulaire), CD142)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure
tisotumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* F3 (factor de coagulación III (tromboplastina, factor tisular), CD142)], *Homo sapiens* anticuerpo monoclonal ; cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYAMSWVRQA PGKGLEWVSS  50
ISGSGDYTYY TDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSP 100
WGYYLDSWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPPS LSASAGDRVT ITCRASQGIS SRLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104)  22-96    145-201    262-322    368-426
                    22''-96''  145''-201''  262''-322''  368''-426''
Intra-L (C23-C104)  23'-88'    134'-194'
                    23'''-88'''  134'''-194'''
Inter-H-L (h 5-CL 126)  221-214'  221''-214'''
Inter-H-H (h 11, h 14)  227-227''  230-230''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tisotumabum vedotinum #

tisotumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* F3 (coagulation factor III (thromboplastin, tissue factor), CD142)], *Homo sapiens* monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

tisotumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* F3 (facteur de coagulation III (thromboplastine, facteur tissulaire), CD142)], *Homo sapiens* anticorps monoclonal conjugué à l'auristatine E;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (227-227'':230-230'')-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)
Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

tisotumab vedotina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* F3 (factor de coagulación III (tromboplastina, factor tisular), CD142)], *Homo sapiens* anticuerpo monoclonal conjugado con la auristatina E;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ5*01) [8.8.11] (1-118) -IGHG1*03, G1m3 (CH1 (119-216), bisagra(217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1D-16*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (227-227'':230-230'')-bisdisulfuro; conjugado, en 3 - 4 restos cisteinil por termino medio, con monometilauristatina E (MMAE), mediante un espaciador escindible de tipo maleimidocaproil-valil-citrulinil-*p*-aminobenciloxicarbonil (mc-val-cit-PABC)
La fracción *vedotina*, la pueden encontrar en el documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NYAMSWVRQA PGKGLEWVSS  50
ISGSGDYTYY TDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSP 100
WGYYLDSWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPPS LSASAGDRVT ITCRASQGIS SRLAWYQQKP EKAPKSLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNSYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126)* 221-214' 221"-214'"
Inter-H-H (h 11, h 14)* 227-227" 230-230"

*Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

trevogrumabum #

trevogrumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* MSTN (myostatin, growth differentiation factor 8, GDF8, GDF-8)], human monoclonal antibody; gamma4 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117) [8.8.13] (1-120) -IGHG4*01 (CH1 (121-218), hinge S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-27*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (226-226":229-229")-bisdisulfide
trévogrumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* MSTN (myostatine, facteur de croissance et de différenciation 8, GDF8, GDF-8)], anticorps monoclonal humain; chaîne lourde gamma4 (1-447) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117) [8.8.13] (1-120) -IGHG4*01 (CH1 (121-218), charnière S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-27*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-bisdisulfure
trevogrumab	inmunoglobulina G4-kappa, anti-[*Homo sapiens* MSTN (miostatina, factor de crecimiento y diferenciación 8, GDF8, GDF-8)], anticuerpo monoclonal humano;

cadena pesada gamma4 (1-447) [*Homo sapiens* VH (IGHV3-23*01 (93.90%) -(IGHD)-IGHJ6*01 T125>I (117) [8.8.13] (1-120) -IGHG4*01 (CH1 (121-218), bisagra S10>P (228) (219-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (121-447)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-27*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQVLESGGD LVQPGGSLRL SCAASGFTFS AYAMTWVRQA PGKGLEWVSA  50
ISGSGGSAYY ADSVKGRFTI SRDNSKNTVY LQMNSLRAED TAVYYCAKDG 100
AWKMSGLDVW GQGTTVIVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT 200
YTCNVDHKPS NTKVDKRVES KYGPPCPPCP APEFLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT 350
LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPAS LSASVGDRVT ITCRASQDIS DYLAWYQQKP GKIPRLLIYT  50
TSTLQSGVPS RFRGSGSGTD FTLTISSLQP EDVATYYCQK YDSAPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	147-203	261-321	367-425
	22"-96"	147"-203"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	134-214'	134"-214'"		
Inter-H-H (h 8, h 11)	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tucatinibum

tucatinib — N^6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-N^4-[3-methyl-4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine

tucatinib — N^6-(4,4-diméthyl-4,5-dihydrooxazol-2-yl)-N^4-[3-méthyl-4-([1,2,4]triazolo[1,5-*a*]pyridin-7-yloxy)phényl]quinazoline-4,6-diamine

tucatinib — N^6-(4,4-dimetil-4,5-dihidrooxazol-2-il)-N^4-[3-metil-4-([1,2,4]triazolo[1,5-*a*]piridin-7-iloxi)fenil]quinazolina-4,6-diamina

$C_{26}H_{24}N_8O_2$



vaborbactamum

vaborbactam — {(3*R*,6*S*)-2-hydroxy-3-[2-(thiophen-2-yl)acetamido]-1,2-oxaborinan-6-yl}acetic acid

vaborbactam	acide {(3*R*,6*S*)-2-hydroxy-3-[2-(thiophén-2-yl)acétamido]-1,2-oxaborinan-6-yl}acétique
vaborbactam	ácido {(3*R*,6*S*)-2-hidroxi-3-[2-(tiofen-2-il)acetamido]-1,2-oxaborinan-6-il}acético



vadastuximabum talirinum #

vadastuximab talirine	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], chimeric monoclonal antibody conjugated to the pyrrolobenzodiazepine (PDB) dimer SGD-1882; gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), hinge (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (226-226":229-229")-bisdisulfide; conjugated, on two site-specific drug attachment engineered cysteines (C239, C239"), to a maximum of 2 pyrrolobenzodiazepine (PDB) dimers SGD-1882, each via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimidocaproyl type linker
vadastuximab talirine	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique conjugué au dimère de pyrrolobenzodiazépine (PDB) SGD-1882; chaîne lourde gamma1 (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), charnière (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur deux cystéines sites de fixation spécifique du linker-produit actif (C239, C239"), à un maximum de 2 dimères de pyrrolobenzodiazépine (PDB) SGD-1882, chacun via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimidocaproyle

vadastuximab talirina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD33 (lectina 3 de tipo Ig-like que liga el ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico conjugado con el dimero de pyirolobenzodiazepina (PDB) SGD-1882;
cadena pesada gamma1 (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (118-215), bisagra (216-230), CH2 S3>C (239) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV14-111*01 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (226-226'':229-229'')-bisdisulfuro; conjugado, en dos císteinas sitios de fijación específicos del linker-producto activo (C239, C239''), con un máximo de 2 dímeros de pirrolobenzodiazepina (PDB) SGD-1882, cada uno mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimidocaproil

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW  50
IYPGDGSTKY NEKFKAKATL TADTSTSTAY MELRSLRSDD TAVYYCASGY 100
EDAMDYWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPCV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT INCKASQDIN SYLSWFQQKP GKAPKTLIYR  50
ANRLVDGVPS RFSGSGSGQD YTLTISSLQP EDFATYYCLQ YDEFPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 220-214' 220''-214'''
Inter-H-H (h 11, h 14) 226-226'' 229-229''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Modified residues / Résidus modifiés / Restos modificados



velmanasum alfa #
velmanase alfa

human lysosomal alpha-mannosidase (Laman, EC3.2.1.24, mannosidase alpha class 2B member 1), produced in CHO (Chinese Hamster Ovary) cells, alfa glycoform

velmanase alfa

alpha mannosidase lysosomiale humaine (Laman, EC3.2.1.24, membre 1 de classe 2B de la mannosidase alpha), produite par la cellule ovarienne de hamster chinois (CHO), forme glycosylée alfa

velmanasa alfa

alfa manosidasa lisosómica humana (Laman, EC3.2.1.24, miembro 1 de la clase 2B de la manosidasa alfa), producida por células ováricas de hamster chino (CHO), forma glicosilada alfa

```
GGYETCPTVQ  PNMLNVHLLP  HTHDDVGWLK  TVDQYFYGIK  NDIQHAGVQY 50
ILDSVISALL  ADPTRRFIYV  EIAFFSRWWH  QQTNATQEVV  RDLVRQGRLE 100
FANGGWVMND  EAATHYGAIV  DQMTLGLRFL  EDTFGNDGRP  RVAWHIDPFG 150
HSREQASLFA  QMGFDGFFFG  RLDYQDKWVR  MQKLEMEQVW  RASTSLKPPT 200
ADLFTGVLPN  GYNPPRNLCW  DVLCVDQPLV  EDPRSPEYNA  KELVDYFLNV 250
ATAQGRYYRT  NHTVMTMGSD  FQYENANMWF  KNLDKLIRLV  NAQQAKGSSV 300
HVLYSTPACY  LWELNKANLT  WSVKHDDFFP  YADGPHQFWT  GYFSSRPALK 350
RYERLSYNFL  QVCNQLEALV  GLAANVGPYG  SGDSAPLNEA  MAVLQHHDAV 400
SGTSRQHVAN  DYARQLAAGW  GPCEVLLSNA  LARLRGFKDH  FTFCQQLNIS 450
ICPLSQTAAR  FQVIVYNPLG  RKVNWMVRLP  VSEGVFVVKD  PNGRTVPSDV 500
VIFPSSDSQA  HPPELLFSAS  LPALGFSTYS  VAQVPRWKPQ  ARAPQPIPRR 550
SWSPALTIEN  EHIRATFDPD  TGLLMEIMNM  NQQLLLPVRQ  TFFWYNASIG 600
DNESDQASGA  YIFRPNQQKP  LPVSRWAQIH  LVKTPLVQEV  HQNFSAWCSQ 650
VVRLYPGQRH  LELEWSVGPI  PVGDTWGKEV  ISRFDTPLET  KGRFYTDSNG 700
REILERRRDY  RPTWKLNQTE  PVAGNYYPVN  TRIYITDGNM  QLTVLTDRSQ 750
GGSSLRDGSL  ELMVHRRLLK  DDGRGVSEPL  MENGSGAWVR  GRHLVLLDTA 800
QAAAAGHRLL  AEQEVLAPQV  VLAPGGGAAY  NLGAPPRTQF  SGLRRDLPPS 850
VHLLTLASWG  PEMVLLRLEH  QFAVGEDSGR  NLSAPVTLNL  RDLFSTFTIT 900
RLQETTLVAN  QLREAASRLK  WTTNTGPTPH  QTPYQLDPAN  ITLEPMEIRT 950
FLASVQWKEV  DG                                          962
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
6-309 219-224 363-423 444-452

Glycosylation sites (potential) / Sites de glycosylation (potentiels) / Posiciones de glicosilación (potenciales)
Asn-84 Asn-261 Asn-318 Asn-448 Asn-596 Asn-602
Asn-643 Asn-717 Asn-783 Asn-881 Asn-940

vesatolimodum
vesatolimod

4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)methyl]phenyl}methyl)-7,8-dihydropteridin-6(5*H*)-one

vésatolimod

4-amino-2-butoxy-8-({3-[(pyrrolidin-1-yl)méthyl]phényl}méthyl)-7,8-dihydroptéridin-6(5*H*)-one

vesatolimod

4-amino-2-butoxi-8-({3-[(pirrolidin-1-il)metil]fenil}metil)-7,8-dihidropteridin-6(5*H*)-ona

$C_{22}H_{30}N_6O_2$



vistusertibum
vistusertib

3-{2,4-bis[(3*S*)-3-methylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-*N*-methylbenzamide

vistusertib

3-{2,4-bis[(3*S*)-3-méthylmorpholin-4-yl]pyrido[2,3-*d*]pyrimidin-7-yl}-*N*-méthylbenzamide

vistusertib

3-{2,4-bis[(3*S*)-3-metilmorfolin-4-il]pirido[2,3-*d*]pirimidin-7-il}-*N*-metilbenzamida

$C_{25}H_{30}N_6O_3$



volanesorsenum

volanesorsen

all-P-ambo-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyluridine

volanésorsen

tout-P-ambo-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyluridine

volanesorsén

todo-P-ambo-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metiluridina

$C_{230}H_{320}N_{63}O_{125}P_{19}S_{19}$

(3'-5')(P-thio)(Amoe-Gmoe-mCmoe-Tmoe-Tmoe-dmC-dT-dT-dG-dT-dmC-dmC-dA-dG-dmC-Tmoe-Tmoe-Tmoe-Amoe-Tmoe)
d (as prefix) = 2'-deoxy
m (as prefix) = 5-methyl
moe (as suffix) = 2'-O-[2-methoxy(ethyl)]

volixibatum

volixibat

N-(3-*O*-benzyl-6-*O*-sulfo-β-D-glucopyranosyl)-*N*'-{3-[(3*S*,4*R*,5*R*)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1*H*-1λ^6-benzothiepin-5-yl]phenyl}urea

volixibat

N-(3-*O*-benzyl-6-*O*-sulfo-β-D-glucopyranosyl)-*N*'-{3-[(3*S*,4*R*,5*R*)-3-butyl-7-(diméthylamino)-3-éthyl-4-hydroxy-1,1-dioxo-2,3,4,5-tétrahydro-1*H*-1λ^6-benzothiépin-5-yl]phényl}urée

volixibat

N-(3-*O*-bencil-6-*O*-sulfo-β-D-glucopiranosil)-*N*'-{3-[(3*S*,4*R*,5*R*)-3-butil-7-(dimetilamino)-3-etil-4-hidroxi-1,1-dioxo-2,3,4,5-tetrahidro-1*H*-1λ^6-benzotiepin-5-il]fenil}urea

$C_{38}H_{51}N_3O_{12}S_2$



voxilaprevirum

voxilaprevir

(1a*R*,5*S*,8*S*,9*S*,10*R*,22a*R*)-5-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluoromethyl)-1-[(1-methylcyclopropanesulfonyl) carbamoyl]cyclopropyl}-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8*H*-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoxaline-8-carboxamide

voxilaprévir

(1a*R*,5*S*,8*S*,9*S*,10*R*,22a*R*)-5-*tert*-butyl-*N*-{(1*R*,2*R*)-2-(difluorométhyl)-1-[(1-méthylcyclopropanesulfonyl) carbamoyl]cyclopropyl}-9-éthyl-18,18-difluoro-14-méthoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tétradécahydro-8*H*-7,10-méthanocyclopropa[18,19] [1,10,3,6]dioxadiazacyclononadécino[11,12-*b*]quinoxaline-8-carboxamide

voxilaprevir

(1a*R*,5*S*,8*S*,9*S*,10*R*,22a*R*)-5-*terc*-butil-*N*-{(1*R*,2*R*)-2-(difluorometil)-1-[(1-metilciclopropanosulfonil) carbamoil]ciclopropil}-9-etil-18,18-difluoro-14-metoxi-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahidro-8*H*-7,10-metanociclopropa[18,19][1,10,3,6] dioxadiazaciclononadecino[11,12-*b*]quinoxalina-8-carboxamida

$C_{40}H_{52}F_4N_6O_9S$



zidebactamum

zidebactam

(1*R*,2*S*,5*R*)-7-oxo-2-{2-[(3*R*)-piperidine-3-carbonyl]hydrazinecarbonyl}-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate

zidébactam

hydrogénosulfate de (1*R*,2*S*,5*R*)-7-oxo-2-{2-[(3*R*)-pipéridine-3-carbonyl]hydrazinecarbonyl}-1,6-diazabicyclo[3.2.1]octan-6-yle

zidebactam

hidrógenosulfato de (1*R*,2*S*,5*R*)-7-oxo-2-{2-[(3*R*)-piperidina-3-carbonil]hidrazinacarbonil}-1,6-diazabiciclo[3.2.1]octan-6-ilo

$C_{13}H_{21}N_5O_7S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 73
Dénominations communes internationales recommandées (DCI Rec.): Liste 73
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 73
(WHO Drug Information, Vol. 29, No. 1, 2015)

p. 64 **albenatidum#**
albenatide
albénatide
albenatida

replace the description and the structure by the following ones
remplacer la description et la structure par les suivantes
sustitúyase la descripción y la estructura por las siguientes

S$^{3.34}$-[1-(3-{[2-(2-{2-[exendin-4 *Heloderma suspectum* precursor-(48-86)-peptidyl (exenatidyl)-L-lysinamide-*N*^{6}-yl]-2-oxo-ethoxy}ethoxy)ethyl]amino}-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl]human serum albumin.
Peptide is synthetic, and human serum albumin is produced in *Saccharomyces cerevisiae.*

S$^{3.34}$-[1-(3-{[2-(2-{2-[précurseur de l'exendin-4 de *Heloderma suspectum*-(48-86)-peptidyl (exénatidyle)-L-lysinamide-*N*^{6}-yl]-2-oxo-éthoxy}éthoxy)éthyl]amino}-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl]albumine sérique humaine.
Le peptide est synthétique et l'albumine sérique humaine est produite par *Saccharomyces cerevisiae*.

S$^{3.34}$-[1-(3-{[2-(2-{2-[precursor de la exendina-4 de *Heloderma suspectum*-(48-86)-peptidil (exenatidilo)-L-lisinamida-*N*^{6}-il]-2-oxo-etoxi}etoxi)etil]amino}-3-oxopropil)-2,5-dioxopirrolidin-3-il]albúmina sérica humana.
El péptido es sintético y la albúmina sérica humana la produce el *Saccharomyces cerevisiae*.

Human albumin / Albumine humaine / Albumina humana

```
DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE 100
CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250
LECADDRADL AKYICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA 350
KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE 450
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL                  585
```

Exenatidyl / Exénatidyle / Exenatidilo

```
HGEGTFTSDL SKQMEEEAVR LFIEWLKNGG PSSGAPPPS-             39
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

53-62 75-91 90-101 124-169 168-177 200-246 245-253 265-279 278-289
316-361 360-369 392-438 437-448 461-477 476-487 514-559 558-567

Modified residue / Résidu modifié / Resto modificado



p. 103 - 104 **pegvaliasum #**

pegvaliase *replace the description by the following one*
pegvaliase *remplacer la description par la suivante*
pegvaliasa *sustitúyase la descripción por la siguiente*

pegylated, recombinant DNA derived *Anabaena variabilis* phenylalanine ammonia lyase mutein (S 503, S 565), produced in *Escherichia coli*:
[503-serine (C>S),565-serine (C>S)]phenylalanine ammonia-lyase (EC 4.3.1.24) *Anabaena variabilis* in which at least 6 lysyl residues are N^6-{6-[ω-methoxypoly(oxyethylene)]hexanoyl} substituted

mutéine (S 503, S 565) de phénylalanine ammoniac-lyase de *Anabaena variabilis*, pégylée, produite par *Escherichia coli* à partir d'ADN recombinant:
[503-sérine (C>S),565-sérine (C>S)]phénylalanine ammoniac-lyase (EC 4.3.1.24) de *Anabaena variabilis* dont au moins 6 résidus lysyl sont N^6-{6-[ω-méthoxypoly(oxyéthylène)]hexanoyl} substitués

muteína (S 503, S 565) de la fenilalanina amoniaco-liasa de *Anabaena variabilis*, pegilada, producida en *Escherichia coli* a partir de ADN recombinante:
[503-serina (C>S),565-serina (C>S)]fenilalanina amoniaco-liasa (EC 4.3.1.24) de *Anabaena variabilis* de cuyos restos lisil 5, por término medio, están N^6-{6-[ω-metoxipoli(oxietileno)]hexanoil} substituidos

Recommended International Nonproprietary Names (Rec. INN): List 74
Dénominations communes internationales recommandées (DCI Rec.): Liste 74
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 74
(WHO Drug Information, Vol. 29, No. 3, 2015)

p. 421 **somapacitanum #**

somapacitan *replace the description and the structure by the following ones*
somapacitan *remplacer la description et la structure par les suivantes*
somapacitán *sustitúyase la descripción y la estructura por las siguientes*

[101-{*S*-[(8*S*,22*S*,27*S*)-8,22,27-tricarboxy-2,10,19,24,29,38,42,42,44-nonaoxo-59-(1*H*-tetrazol-5-yl)-12,15,31,34-tetraoxa-42λ^6-thia-3,9,18,23,28,37,43-heptaazanonapentacontan-1-yl]-L-cysteine}]human somatropin

[101-{*S*-[(8*S*,22*S*,27*S*)-8,22,27-tricarboxy-2,10,19,24,29,38,42,42,44-nonaoxo-59-(1*H*-tétrazol-5-yl)-12,15,31,34-tétraoxa-42λ^6-thia-3,9,18,23,28,37,43-heptaazanonapentacontan-1-yl]-L-cystéine}]somatropine humaine

[101-{*S*-[(8*S*,22*S*,27*S*)-8,22,27-tricarboxi-2,10,19,24,29,38,42,42,44-nonaoxo-59-(1*H*-tetrazol-5-il)-12,15,31,34-tetraoxa-42λ^6-tia-3,9,18,23,28,37,43-heptaazanonapentacontan-1-il]-L-cisteina}]somatropina humana

Sequence / Séquence / Secuencia

```
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT 50
SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
CVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS 150
HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F          191
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
53-165 182-189

Modified residue / Résidu modifié / Resto modificado



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.